research topics biotech

200+ Biotechnology Research Topics: Let’s Shape the Future

In the dynamic landscape of scientific exploration, biotechnology stands at the forefront, revolutionizing the way we approach healthcare, agriculture, and environmental sustainability. This interdisciplinary field encompasses a vast array of research topics that hold the potential to reshape our world. 

In this blog post, we will delve into the realm of biotechnology research topics, understanding their significance and exploring the diverse avenues that researchers are actively investigating.

Overview of Biotechnology Research

Table of Contents

Biotechnology, at its core, involves the application of biological systems, organisms, or derivatives to develop technologies and products for the benefit of humanity. 

The scope of biotechnology research is broad, covering areas such as genetic engineering, biomedical engineering, environmental biotechnology, and industrial biotechnology. Its interdisciplinary nature makes it a melting pot of ideas and innovations, pushing the boundaries of what is possible.

How to Select The Best Biotechnology Research Topics?

• Identify Your Interests

Start by reflecting on your own interests within the broad field of biotechnology. What aspects of biotechnology excite you the most? Identifying your passion will make the research process more engaging.

• Stay Informed About Current Trends

Keep up with the latest developments and trends in biotechnology. Subscribe to scientific journals, attend conferences, and follow reputable websites to stay informed about cutting-edge research. This will help you identify gaps in knowledge or areas where advancements are needed.

• Consider Societal Impact

Evaluate the potential societal impact of your chosen research topic. How does it contribute to solving real-world problems? Biotechnology has applications in healthcare, agriculture, environmental conservation, and more. Choose a topic that aligns with the broader goal of improving quality of life or addressing global challenges.

• Assess Feasibility and Resources

Evaluate the feasibility of your research topic. Consider the availability of resources, including laboratory equipment, funding, and expertise. A well-defined and achievable research plan will increase the likelihood of successful outcomes.

• Explore Innovation Opportunities

Look for opportunities to contribute to innovation within the field. Consider topics that push the boundaries of current knowledge, introduce novel methodologies, or explore interdisciplinary approaches. Innovation often leads to groundbreaking discoveries.

• Consult with Mentors and Peers

Seek guidance from mentors, professors, or colleagues who have expertise in biotechnology. Discuss your research interests with them and gather insights. They can provide valuable advice on the feasibility and significance of your chosen topic.

• Balance Specificity and Breadth

Strike a balance between biotechnology research topics that are specific enough to address a particular aspect of biotechnology and broad enough to allow for meaningful research. A topic that is too narrow may limit your research scope, while one that is too broad may lack focus.

• Consider Ethical Implications

Be mindful of the ethical implications of your research. Biotechnology, especially areas like genetic engineering, can raise ethical concerns. Ensure that your chosen topic aligns with ethical standards and consider how your research may impact society.

• Evaluate Industry Relevance

Consider the relevance of your research topic to the biotechnology industry. Industry-relevant research has the potential for practical applications and may attract funding and collaboration opportunities.

• Stay Flexible and Open-Minded

Be open to refining or adjusting your research topic as you delve deeper into the literature and gather more information. Flexibility is key to adapting to new insights and developments in the field.

200+ Biotechnology Research Topics: Category-Wise

Genetic engineering.

• CRISPR-Cas9: Recent Advances and Applications
• Gene Editing for Therapeutic Purposes: Opportunities and Challenges
• Precision Medicine and Personalized Genomic Therapies
• Genome Sequencing Technologies: Current State and Future Prospects
• Synthetic Biology: Engineering New Life Forms
• Genetic Modification of Crops for Improved Yield and Resistance
• Ethical Considerations in Human Genetic Engineering
• Gene Therapy for Neurological Disorders
• Epigenetics: Understanding the Role of Gene Regulation
• CRISPR in Agriculture: Enhancing Crop Traits

Biomedical Engineering

• Tissue Engineering: Creating Organs in the Lab
• 3D Printing in Biomedical Applications
• Advances in Drug Delivery Systems
• Nanotechnology in Medicine: Theranostic Approaches
• Bioinformatics and Computational Biology in Biomedicine
• Wearable Biomedical Devices for Health Monitoring
• Stem Cell Research and Regenerative Medicine
• Precision Oncology: Tailoring Cancer Treatments
• Biomaterials for Biomedical Applications
• Biomechanics in Biomedical Engineering

Environmental Biotechnology

• Bioremediation of Polluted Environments
• Waste-to-Energy Technologies: Turning Trash into Power
• Sustainable Agriculture Practices Using Biotechnology
• Bioaugmentation in Wastewater Treatment
• Microbial Fuel Cells: Harnessing Microorganisms for Energy
• Biotechnology in Conservation Biology
• Phytoremediation: Plants as Environmental Cleanup Agents
• Aquaponics: Integration of Aquaculture and Hydroponics
• Biodiversity Monitoring Using DNA Barcoding
• Algal Biofuels: A Sustainable Energy Source

Industrial Biotechnology

• Enzyme Engineering for Industrial Applications
• Bioprocessing and Bio-manufacturing Innovations
• Industrial Applications of Microbial Biotechnology
• Bio-based Materials: Eco-friendly Alternatives
• Synthetic Biology for Industrial Processes
• Metabolic Engineering for Chemical Production
• Industrial Fermentation: Optimization and Scale-up
• Biocatalysis in Pharmaceutical Industry
• Advanced Bioprocess Monitoring and Control
• Green Chemistry: Sustainable Practices in Industry

Emerging Trends in Biotechnology

• CRISPR-Based Diagnostics: A New Era in Disease Detection
• Neurobiotechnology: Advancements in Brain-Computer Interfaces
• Advances in Nanotechnology for Healthcare
• Computational Biology: Modeling Biological Systems
• Organoids: Miniature Organs for Drug Testing
• Genome Editing in Non-Human Organisms
• Biotechnology and the Internet of Things (IoT)
• Exosome-based Therapeutics: Potential Applications
• Biohybrid Systems: Integrating Living and Artificial Components
• Metagenomics: Exploring Microbial Communities

Ethical and Social Implications

• Ethical Considerations in CRISPR-Based Gene Editing
• Privacy Concerns in Personal Genomic Data Sharing
• Biotechnology and Social Equity: Bridging the Gap
• Dual-Use Dilemmas in Biotechnological Research
• Informed Consent in Genetic Testing and Research
• Accessibility of Biotechnological Therapies: Global Perspectives
• Human Enhancement Technologies: Ethical Perspectives
• Biotechnology and Cultural Perspectives on Genetic Modification
• Social Impact Assessment of Biotechnological Interventions
• Intellectual Property Rights in Biotechnology

Computational Biology and Bioinformatics

• Machine Learning in Biomedical Data Analysis
• Network Biology: Understanding Biological Systems
• Structural Bioinformatics: Predicting Protein Structures
• Data Mining in Genomics and Proteomics
• Systems Biology Approaches in Biotechnology
• Comparative Genomics: Evolutionary Insights
• Bioinformatics Tools for Drug Discovery
• Cloud Computing in Biomedical Research
• Artificial Intelligence in Diagnostics and Treatment
• Computational Approaches to Vaccine Design

Health and Medicine

• Vaccines and Immunotherapy: Advancements in Disease Prevention
• CRISPR-Based Therapies for Genetic Disorders
• Infectious Disease Diagnostics Using Biotechnology
• Telemedicine and Biotechnology Integration
• Biotechnology in Rare Disease Research
• Gut Microbiome and Human Health
• Precision Nutrition: Personalized Diets Using Biotechnology
• Biotechnology Approaches to Combat Antibiotic Resistance
• Point-of-Care Diagnostics for Global Health
• Biotechnology in Aging Research and Longevity

Agricultural Biotechnology

• CRISPR and Gene Editing in Crop Improvement
• Precision Agriculture: Integrating Technology for Crop Management
• Biotechnology Solutions for Food Security
• RNA Interference in Pest Control
• Vertical Farming and Biotechnology
• Plant-Microbe Interactions for Sustainable Agriculture
• Biofortification: Enhancing Nutritional Content in Crops
• Smart Farming Technologies and Biotechnology
• Precision Livestock Farming Using Biotechnological Tools
• Drought-Tolerant Crops: Biotechnological Approaches

Biotechnology and Education

• Integrating Biotechnology into STEM Education
• Virtual Labs in Biotechnology Teaching
• Biotechnology Outreach Programs for Schools
• Online Courses in Biotechnology: Accessibility and Quality
• Hands-on Biotechnology Experiments for Students
• Bioethics Education in Biotechnology Programs
• Role of Internships in Biotechnology Education
• Collaborative Learning in Biotechnology Classrooms
• Biotechnology Education for Non-Science Majors
• Addressing Gender Disparities in Biotechnology Education

Funding and Policy

• Government Funding Initiatives for Biotechnology Research
• Private Sector Investment in Biotechnology Ventures
• Impact of Intellectual Property Policies on Biotechnology
• Ethical Guidelines for Biotechnological Research
• Public-Private Partnerships in Biotechnology
• Regulatory Frameworks for Gene Editing Technologies
• Biotechnology and Global Health Policy
• Biotechnology Diplomacy: International Collaboration
• Funding Challenges in Biotechnology Startups
• Role of Nonprofit Organizations in Biotechnological Research

Biotechnology and the Environment

• Biotechnology for Air Pollution Control
• Microbial Sensors for Environmental Monitoring
• Remote Sensing in Environmental Biotechnology
• Climate Change Mitigation Using Biotechnology
• Circular Economy and Biotechnological Innovations
• Marine Biotechnology for Ocean Conservation
• Bio-inspired Design for Environmental Solutions
• Ecological Restoration Using Biotechnological Approaches
• Impact of Biotechnology on Biodiversity
• Biotechnology and Sustainable Urban Development

Biosecurity and Biosafety

• Biosecurity Measures in Biotechnology Laboratories
• Dual-Use Research and Ethical Considerations
• Global Collaboration for Biosafety in Biotechnology
• Security Risks in Gene Editing Technologies
• Surveillance Technologies in Biotechnological Research
• Biosecurity Education for Biotechnology Professionals
• Risk Assessment in Biotechnology Research
• Bioethics in Biodefense Research
• Biotechnology and National Security
• Public Awareness and Biosecurity in Biotechnology

Industry Applications

• Biotechnology in the Pharmaceutical Industry
• Bioprocessing Innovations for Drug Production
• Industrial Enzymes and Their Applications
• Biotechnology in Food and Beverage Production
• Applications of Synthetic Biology in Industry
• Biotechnology in Textile Manufacturing
• Cosmetic and Personal Care Biotechnology
• Biotechnological Approaches in Renewable Energy
• Advanced Materials Production Using Biotechnology
• Biotechnology in the Automotive Industry

Miscellaneous Topics

• DNA Barcoding in Species Identification
• Bioart: The Intersection of Biology and Art
• Biotechnology in Forensic Science
• Using Biotechnology to Preserve Cultural Heritage
• Biohacking: DIY Biology and Citizen Science
• Microbiome Engineering for Human Health
• Environmental DNA (eDNA) for Biodiversity Monitoring
• Biotechnology and Astrobiology: Searching for Life Beyond Earth
• Biotechnology and Sports Science
• Biotechnology and the Future of Space Exploration

Challenges and Ethical Considerations in Biotechnology Research

As biotechnology continues to advance, it brings forth a set of challenges and ethical considerations. Biosecurity concerns, especially in the context of gene editing technologies, raise questions about the responsible use of powerful tools like CRISPR. 

Ethical implications of genetic manipulation, such as the creation of designer babies, demand careful consideration and international collaboration to establish guidelines and regulations. 

Moreover, the environmental and social impact of biotechnological interventions must be thoroughly assessed to ensure responsible and sustainable practices.

Funding and Resources for Biotechnology Research

The pursuit of biotechnology research topics requires substantial funding and resources. Government grants and funding agencies play a pivotal role in supporting research initiatives. 

Simultaneously, the private sector, including biotechnology companies and venture capitalists, invest in promising projects. Collaboration and partnerships between academia, industry, and nonprofit organizations further amplify the impact of biotechnological research.

Future Prospects of Biotechnology Research

As we look to the future, the integration of biotechnology with other scientific disciplines holds immense potential. Collaborations with fields like artificial intelligence, materials science, and robotics may lead to unprecedented breakthroughs. 

The development of innovative technologies and their application to global health and sustainability challenges will likely shape the future of biotechnology.

In conclusion, biotechnology research is a dynamic and transformative force with the potential to revolutionize multiple facets of our lives. The exploration of diverse biotechnology research topics, from genetic engineering to emerging trends like synthetic biology and nanobiotechnology, highlights the breadth of possibilities within this field. 

However, researchers must navigate challenges and ethical considerations to ensure that biotechnological advancements are used responsibly for the betterment of society. 

With continued funding, collaboration, and a commitment to ethical practices, the future of biotechnology research holds exciting promise, propelling us towards a more sustainable and technologically advanced world.

Related Posts

Step by Step Guide on The Best Way to Finance Car

The Best Way on How to Get Fund For Business to Grow it Efficiently

Research Topics & Ideas

Biotechnology and Genetic Engineering

If you’re just starting out exploring biotechnology-related topics for your dissertation, thesis or research project, you’ve come to the right place. In this post, we’ll help kickstart your research topic ideation process by providing a hearty list of research topics and ideas , including examples from recent studies.

PS – This is just the start…

We know it’s exciting to run through a list of research topics, but please keep in mind that this list is just a starting point . To develop a suitable research topic, you’ll need to identify a clear and convincing research gap , and a viable plan  to fill that gap.

If this sounds foreign to you, check out our free research topic webinar that explores how to find and refine a high-quality research topic, from scratch. Alternatively, if you’d like hands-on help, consider our 1-on-1 coaching service .

Biotechnology Research Topic Ideas

Below you’ll find a list of biotech and genetic engineering-related research topics ideas. These are intentionally broad and generic , so keep in mind that you will need to refine them a little. Nevertheless, they should inspire some ideas for your project.

• Developing CRISPR-Cas9 gene editing techniques for treating inherited blood disorders.
• The use of biotechnology in developing drought-resistant crop varieties.
• The role of genetic engineering in enhancing biofuel production efficiency.
• Investigating the potential of stem cell therapy in regenerative medicine for spinal cord injuries.
• Developing gene therapy approaches for the treatment of rare genetic diseases.
• The application of biotechnology in creating biodegradable plastics from plant materials.
• The use of gene editing to enhance nutritional content in staple crops.
• Investigating the potential of microbiome engineering in treating gastrointestinal diseases.
• The role of genetic engineering in vaccine development, with a focus on mRNA vaccines.
• Biotechnological approaches to combat antibiotic-resistant bacteria.
• Developing genetically engineered organisms for bioremediation of polluted environments.
• The use of gene editing to create hypoallergenic food products.
• Investigating the role of epigenetics in cancer development and therapy.
• The application of biotechnology in developing rapid diagnostic tools for infectious diseases.
• Genetic engineering for the production of synthetic spider silk for industrial use.
• Biotechnological strategies for improving animal health and productivity in agriculture.
• The use of gene editing in creating organ donor animals compatible with human transplantation.
• Developing algae-based bioreactors for carbon capture and biofuel production.
• The role of biotechnology in enhancing the shelf life and quality of fresh produce.
• Investigating the ethics and social implications of human gene editing technologies.
• The use of CRISPR technology in creating models for neurodegenerative diseases.
• Biotechnological approaches for the production of high-value pharmaceutical compounds.
• The application of genetic engineering in developing pest-resistant crops.
• Investigating the potential of gene therapy in treating autoimmune diseases.
• Developing biotechnological methods for producing environmentally friendly dyes.

Biotech & GE Research Topic Ideas (Continued)

• The use of genetic engineering in enhancing the efficiency of photosynthesis in plants.
• Biotechnological innovations in creating sustainable aquaculture practices.
• The role of biotechnology in developing non-invasive prenatal genetic testing methods.
• Genetic engineering for the development of novel enzymes for industrial applications.
• Investigating the potential of xenotransplantation in addressing organ donor shortages.
• The use of biotechnology in creating personalised cancer vaccines.
• Developing gene editing tools for combating invasive species in ecosystems.
• Biotechnological strategies for improving the nutritional quality of plant-based proteins.
• The application of genetic engineering in enhancing the production of renewable energy sources.
• Investigating the role of biotechnology in creating advanced wound care materials.
• The use of CRISPR for targeted gene activation in regenerative medicine.
• Biotechnological approaches to enhancing the sensory qualities of plant-based meat alternatives.
• Genetic engineering for improving the efficiency of water use in agriculture.
• The role of biotechnology in developing treatments for rare metabolic disorders.
• Investigating the use of gene therapy in age-related macular degeneration.
• The application of genetic engineering in developing allergen-free nuts.
• Biotechnological innovations in the production of sustainable and eco-friendly textiles.
• The use of gene editing in studying and treating sleep disorders.
• Developing biotechnological solutions for the management of plastic waste.
• The role of genetic engineering in enhancing the production of essential vitamins in crops.
• Biotechnological approaches to the treatment of chronic pain conditions.
• The use of gene therapy in treating muscular dystrophy.
• Investigating the potential of biotechnology in reversing environmental degradation.
• The application of genetic engineering in improving the shelf life of vaccines.
• Biotechnological strategies for enhancing the efficiency of mineral extraction in mining.

Recent Biotech & GE-Related Studies

While the ideas we’ve presented above are a decent starting point for finding a research topic in biotech, they are fairly generic and non-specific. So, it helps to look at actual studies in the biotech space to see how this all comes together in practice.

Below, we’ve included a selection of recent studies to help refine your thinking. These are actual studies,  so they can provide some useful insight as to what a research topic looks like in practice.

• Genetic modifications associated with sustainability aspects for sustainable developments (Sharma et al., 2022)
• Review On: Impact of Genetic Engineering in Biotic Stresses Resistance Crop Breeding (Abebe & Tafa, 2022)
• Biorisk assessment of genetic engineering — lessons learned from teaching interdisciplinary courses on responsible conduct in the life sciences (Himmel et al., 2022)
• Genetic Engineering Technologies for Improving Crop Yield and Quality (Ye et al., 2022)
• Legal Aspects of Genetically Modified Food Product Safety for Health in Indonesia (Khamdi, 2022)
• Innovative Teaching Practice and Exploration of Genetic Engineering Experiment (Jebur, 2022)
• Efficient Bacterial Genome Engineering throughout the Central Dogma Using the Dual-Selection Marker tetAOPT (Bayer et al., 2022)
• Gene engineering: its positive and negative effects (Makrushina & Klitsenko, 2022)
• Advances of genetic engineering in streptococci and enterococci (Kurushima & Tomita, 2022)
• Genetic Engineering of Immune Evasive Stem Cell-Derived Islets (Sackett et al., 2022)
• Establishment of High-Efficiency Screening System for Gene Deletion in Fusarium venenatum TB01 (Tong et al., 2022)
• Prospects of chloroplast metabolic engineering for developing nutrient-dense food crops (Tanwar et al., 2022)
• Genetic research: legal and ethical aspects (Rustambekov et al., 2023). Non-transgenic Gene Modulation via Spray Delivery of Nucleic Acid/Peptide Complexes into Plant Nuclei and Chloroplasts (Thagun et al., 2022)
• The role of genetic breeding in food security: A review (Sam et al., 2022). Biotechnology: use of available carbon sources on the planet to generate alternatives energy (Junior et al., 2022)
• Biotechnology and biodiversity for the sustainable development of our society (Jaime, 2023) Role Of Biotechnology in Agriculture (Shringarpure, 2022)
• Plants That Can be Used as Plant-Based Edible Vaccines; Current Situation and Recent Developments (İsmail, 2022)

As you can see, these research topics are a lot more focused than the generic topic ideas we presented earlier. So, in order for you to develop a high-quality research topic, you’ll need to get specific and laser-focused on a specific context with specific variables of interest.  In the video below, we explore some other important things you’ll need to consider when crafting your research topic.

Get 1-On-1 Help

If you’re still unsure about how to find a quality research topic, check out our Research Topic Kickstarter service, which is the perfect starting point for developing a unique, well-justified research topic.

You Might Also Like:

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

• Print Friendly

Top 50 Research Topics in Biotechnology

Table of Contents

Biotechnology

Research in biotechnology can helps in bringing massive changes in humankind and lead to a better life. In the last few years, there have been so many leaps, and paces of innovations as scientists worldwide worked to develop and produce novel mRNA vaccinations and brought some significant developments in biotechnology. During this period, they also faced many challenges. Disturbances in the supply chain and the pandemic significantly impacted biotech labs and researchers, forcing lab managers to become ingenious in buying lab supplies, planning experiments, and using technology for maintaining research schedules.

At the beginning of 2022, existing biotech research projects are discovering progress in medicines, vaccines, disease treatment and the human body, immunology, and some viruses such as coronavirus that had such a destructive impact that we could never have expected.

The Biotech Research Technique is changing

How research is being done is changing, as also how scientists are conducting it. Affected by both B2C eCommerce and growing independence in remote and cloud-dependent working, most of the biotechnology labs are going through some digital transformations. This implies more software, automation, and AI in the biotech lab, along with some latest digital procurement plans and integrated systems for various lab operations.

In this article, we’ll discuss research topics in biotechnology for students, biotechnology project topics, biotechnology research topics for undergraduates, biotechnology thesis topics, biotechnology research topics for college students, biotechnology research paper topics, biotechnology dissertation topics, biotechnology project ideas for high school, medical biotechnology topics for presentation, research topics for life science , research topics on biotechnology , medical biotechnology topics, recent research topics in biotechnology, mini project ideas for biotechnology, pharmaceutical biotechnology topics, plant biotechnology research topics, research topics in genetics and biotechnology, final year project topics for biotechnology, biotech research project ideas, health biotechnology topics, industrial biotechnology topics, agricultural biotechnology project topics and biology thesis topics.

Look at some of the top trends in biotech research and recent Biotechnology Topics that are bringing massive changes in this vast world of science, resulting in some innovation in life sciences and biotechnology ideas .

• Development of vaccine: Development of mRNA has been done since 1989 but has accelerated to combat the pandemic. As per many researchers, mRNA vaccines can change infectious disease control as it is a prophylactic means of disease prevention for various diseases such as flu, HIV, etc.
• Respiratory viruses: More and more research is being done because understanding those viruses will assist in getting better protection, prohibition, and promising treatments for respiratory viruses.
• Microvesicles and extracellular vesicles are now being focused on because of their involvement in the transportation of mRNA, miRNA, and proteins. But in what other ways can they give support to the human body? So many unknown roles of microvesicles and extracellular vesicles should be discovered.
• RNA-based Therapeutics: Researchers focus on RNA-based therapeutics such as CAR T cells, other gene/cell therapeutics, small molecular drugs to treat more diseases and other prophylactic purposes.
• Metabolism in cancers and other diseases: Metabolism helps convert energy and represent the chemical reactions that will sustain life. Nowadays, research is being done to study metabolism in cancers and immune cells to uncover novel ways to approach treatment and prohibition of a specific illness.

All of the ongoing research keeps the potential to bring changes in the quality of life of millions of people, prohibit and do treatment of illnesses that at present have a very high rate of mortality, and change healthcare across the world.

We share different job or exam notices on Labmonk Notice Board . You can search “ Labmonk Notice Board ” on google search to check out latest jobs of your field.

Click the page numbers below to read more on this topic.

Leave a Comment Cancel reply

Save my name, email, and website in this browser for the next time I comment.

Biotechnology Research Paper Topics

This collection of biotechnology research paper topics provides the list of 10 potential topics for research papers and overviews the history of biotechnology.

Academic Writing, Editing, Proofreading, And Problem Solving Services

Get 10% off with 24start discount code, 1. animal breeding: genetic methods.

Modern animal breeding relies on scientific methods to control production of domesticated animals, both livestock and pets, which exhibit desired physical and behavioral traits. Genetic technology aids animal breeders to attain nutritional, medical, recreational, and fashion standards demanded by consumers for animal products including meat, milk, eggs, leather, wool, and pharmaceuticals. Animals are also genetically designed to meet labor and sporting requirements for speed and endurance, conformation and beauty ideals to win show competitions, and intelligence levels to perform obediently at tasks such as herding, hunting, and tracking. By the late twentieth century, genetics and mathematical models were appropriated to identify the potential of immature animals. DNA markers indicate how young animals will mature, saving breeders money by not investing in animals lacking genetic promise. Scientists also successfully transplanted sperm-producing stem cells with the goal of restoring fertility to barren breeding animals. At the National Animal Disease Center in Ames, Iowa, researchers created a gene-based test, which uses a cloned gene of the organism that causes Johne’s disease in cattle in order to detect that disease to avert epidemics. Researchers also began mapping the dog genome and developing molecular techniques to evaluate canine chromosomes in the Quantitative Trait Loci (QTL). Bioinformatics incorporates computers to analyze genetic material. Some tests were developed to diagnose many of several hundred genetic canine diseases including hip dysplasia and progressive retinal atrophy (PRA). A few breed organizations modified standards to discourage breeding of genetically flawed animals and promote heterozygosity.

2. Antibacterial Chemotherapy

In the early years of the twentieth century, the search for agents that would be effective against internal infections proceeded along two main routes. The first was a search for naturally occurring substances that were effective against microorganisms (antibiosis). The second was a search for chemicals that would have the same effect (chemotherapy). Despite the success of penicillin in the 1940s, the major early advances in the treatment of infection occurred not through antibiosis but through chemotherapy. The principle behind chemotherapy was that there was a relationship between chemical structure and pharmacological action. The founder of this concept was Paul Erhlich (1854–1915). An early success came in 1905 when atoxyl (an organic arsenic compound) was shown to destroy trypanosomes, the microbes that caused sleeping sickness. Unfortunately, atoxyl also damaged the optic nerve. Subsequently, Erhlich and his co-workers synthesized and tested hundreds of related arsenic compounds. Ehrlich was a co-recipient (with Ilya Ilyich Mechnikov) of the Nobel Prize in medicine in 1908 for his work on immunity. Success in discovering a range of effective antibacterial drugs had three important consequences: it brought a range of important diseases under control for the first time; it provided a tremendous stimulus to research workers and opened up new avenues of research; and in the resulting commercial optimism, it led to heavy postwar investment in the pharmaceutical industry. The therapeutic revolution had begun.

3. Artificial Insemination and in Vitro Fertilization

Artificial insemination (AI) involves the extraction and collection of semen together with techniques for depositing semen in the uterus in order to achieve successful fertilization and pregnancy. Throughout the twentieth century, the approach has offered animal breeders the advantage of being able to utilize the best available breeding stock and at the correct time within the female reproductive cycle, but without the limitations of having the animals in the same location. AI has been applied most intensively within the dairy and beef cattle industries and to a lesser extent horse breeding and numerous other domesticated species.

Many of the techniques involved in artificial insemination would lay the foundation for in vitro fertilization (IVF) in the latter half of the twentieth century. IVF refers to the group of technologies that allow fertilization to take place outside the body involving the retrieval of ova or eggs from the female and sperm from the male, which are then combined in artificial, or ‘‘test tube,’’ conditions leading to fertilization. The fertilized eggs then continue to develop for several days ‘‘in culture’’ until being transferred to the female recipient to continue developing within the uterus.

4. Biopolymers

Biopolymers are natural polymers, long-chained molecules (macromolecules) consisting mostly of a repeated composition of building blocks or monomers that are formed and utilized by living organisms. Each group of biopolymers is composed of different building blocks, for example chains of sugar molecules form starch (a polysaccharide), chains of amino acids form proteins and peptides, and chains of nucleic acid form DNA and RNA (polynucleotides). Biopolymers can form gels, fibers, coatings, and films depending on the specific polymer, and serve a variety of critical functions for cells and organisms. Proteins including collagens, keratins, silks, tubulins, and actin usually form structural composites or scaffolding, or protective materials in biological systems (e.g., spider silk). Polysaccharides function in molecular recognition at cell membrane surfaces, form capsular barrier layers around cells, act as emulsifiers and adhesives, and serve as skeletal or architectural materials in plants. In many cases these polymers occur in combination with proteins to form novel composite structures such as invertebrate exoskeletons or microbial cell walls, or with lignin in the case of plant cell walls.

The use of the word ‘‘cloning’’ is fraught with confusion and inconsistency, and it is important at the outset of this discussion to offer definitional clarification. For instance, in the 1997 article by Ian Wilmut and colleagues announcing the birth of the first cloned adult vertebrate (a ewe, Dolly the sheep) from somatic cell nuclear transfer, the word clone or cloning was never used, and yet the announcement raised considerable disquiet about the prospect of cloned human beings. In a desire to avoid potentially negative forms of language, many prefer to substitute ‘‘cell expansion techniques’’ or ‘‘therapeutic cloning’’ for cloning. Cloning has been known for centuries as a horticultural propagation method: for example, plants multiplied by grafting, budding, or cuttings do not differ genetically from the original plant. The term clone entered more common usage as a result of a speech in 1963 by J.B.S. Haldane based on his paper, ‘‘Biological possibilities for the human species of the next ten-thousand years.’’ Notwithstanding these notes of caution, we can refer to a number of processes as cloning. At the close of the twentieth century, such techniques had not yet progressed to the ability to bring a cloned human to full development; however, the ability to clone cells from an adult human has potential to treat diseases. International policymaking in the late 1990s sought to distinguish between the different end uses for somatic cell nuclear transfer resulting in the widespread adoption of the distinction between ‘‘reproductive’’ and ‘‘therapeutic’’ cloning. The function of the distinction has been to permit the use (in some countries) of the technique to generate potentially beneficial therapeutic applications from embryonic stem cell technology whilst prohibiting its use in human reproduction. In therapeutic applications, nuclear transfer from a patient’s cells into an enucleated ovum is used to create genetically identical embryos that would be grown in vitro but not be allowed to continue developing to become a human being. The resulting cloned embryos could be used as a source from which to produce stem cells that can then be induced to specialize into the specific type of tissue required by the patient (such as skin for burns victims, brain neuron cells for Parkinson’s disease sufferers, or pancreatic cells for diabetics). The rationale is that because the original nuclear material is derived from a patient’s adult tissue, the risks of rejection of such cells by the immune system are reduced.

6. Gene Therapy

In 1971, Australian Nobel laureate Sir F. MacFarlane Burnet thought that gene therapy (introducing genes into body tissue, usually to treat an inherited genetic disorder) looked more and more like a case of the emperor’s new clothes. Ethical issues aside, he believed that practical considerations forestalled possibilities for any beneficial gene strategy, then or probably ever. Bluntly, he wrote: ‘‘little further advance can be expected from laboratory science in the handling of ‘intrinsic’ types of disability and disease.’’ Joshua Lederberg and Edward Tatum, 1958 Nobel laureates, theorized in the 1960s that genes might be altered or replaced using viral vectors to treat human diseases. Stanfield Rogers, working from the Oak Ridge National Laboratory in 1970, had tried but failed to cure argininemia (a genetic disorder of the urea cycle that causes neurological damage in the form of mental retardation, seizures, and eventually death) in two German girls using Swope papilloma virus. Martin Cline at the University of California in Los Angeles, made the second failed attempt a decade later. He tried to correct the bone marrow cells of two beta-thalassemia patients, one in Israel and the other in Italy. What Cline’s failure revealed, however, was that many researchers who condemned his trial as unethical were by then working toward similar goals and targeting different diseases with various delivery methods. While Burnet’s pessimism finally proved to be wrong, progress in gene therapy was much slower than antibiotic or anticancer chemotherapy developments over the same period of time. While gene therapy had limited success, it nevertheless remained an active area for research, particularly because the Human Genome Project, begun in 1990, had resulted in a ‘‘rough draft’’ of all human genes by 2001, and was completed in 2003. Gene mapping created the means for analyzing the expression patterns of hundreds of genes involved in biological pathways and for identifying single nucleotide polymorphisms (SNPs) that have diagnostic and therapeutic potential for treating specific diseases in individuals. In the future, gene therapies may prove effective at protecting patients from adverse drug reactions or changing the biochemical nature of a person’s disease. They may also target blood vessel formation in order to prevent heart disease or blindness due to macular degeneration or diabetic retinopathy. One of the oldest ideas for use of gene therapy is to produce anticancer vaccines. One method involves inserting a granulocyte-macrophage colony-stimulating factor gene into prostate tumor cells removed in surgery. The cells then are irradiated to prevent any further cancer and injected back into the same patient to initiate an immune response against any remaining metastases. Whether or not such developments become a major treatment modality, no one now believes, as MacFarland Burnet did in 1970, that gene therapy science has reached an end in its potential to advance health.

7. Genetic Engineering

The term ‘‘genetic engineering’’ describes molecular biology techniques that allow geneticists to analyze and manipulate deoxyribonucleic acid (DNA). At the close of the twentieth century, genetic engineering promised to revolutionize many industries, including microbial biotechnology, agriculture, and medicine. It also sparked controversy over potential health and ecological hazards due to the unprecedented ability to bypass traditional biological reproduction.

For centuries, if not millennia, techniques have been employed to alter the genetic characteristics of animals and plants to enhance specifically desired traits. In a great many cases, breeds with which we are most familiar bear little resemblance to the wild varieties from which they are derived. Canine breeds, for instance, have been selectively tailored to changing esthetic tastes over many years, altering their appearance, behavior and temperament. Many of the species used in farming reflect long-term alterations to enhance meat, milk, and fleece yields. Likewise, in the case of agricultural varieties, hybridization and selective breeding have resulted in crops that are adapted to specific production conditions and regional demands. Genetic engineering differs from these traditional methods of plant and animal breeding in some very important respects. First, genes from one organism can be extracted and recombined with those of another (using recombinant DNA, or rDNA, technology) without either organism having to be of the same species. Second, removing the requirement for species reproductive compatibility, new genetic combinations can be produced in a much more highly accelerated way than before. Since the development of the first rDNA organism by Stanley Cohen and Herbert Boyer in 1973, a number of techniques have been found to produce highly novel products derived from transgenic plants and animals.

At the same time, there has been an ongoing and ferocious political debate over the environmental and health risks to humans of genetically altered species. The rise of genetic engineering may be characterized by developments during the last three decades of the twentieth century.

8. Genetic Screening and Testing

The menu of genetic screening and testing technologies now available in most developed countries increased rapidly in the closing years of the twentieth century. These technologies emerged within the context of rapidly changing social and legal contexts with regard to the medicalization of pregnancy and birth and the legalization of abortion. The earliest genetic screening tests detected inborn errors of metabolism and sex-linked disorders. Technological innovations in genomic mapping and DNA sequencing, together with an explosion in research on the genetic basis of disease which culminated in the Human Genome Project (HGP), led to a range of genetic screening and testing for diseases traditionally recognized as genetic in origin and for susceptibility to more common diseases such as certain types of familial cancer, cardiac conditions, and neurological disorders among others. Tests were also useful for forensic, or nonmedical, purposes. Genetic screening techniques are now available in conjunction with in vitro fertilization and other types of reproductive technologies, allowing the screening of fertilized embryos for certain genetic mutations before selection for implantation. At present selection is purely on disease grounds and selection for other traits (e.g., for eye or hair color, intelligence, height) cannot yet be done, though there are concerns for eugenics and ‘‘designer babies.’’ Screening is available for an increasing number of metabolic diseases through tandem mass spectrometry, which uses less blood per test, allows testing for many conditions simultaneously, and has a very low false-positive rate as compared to conventional Guthrie testing. Finally, genetic technologies are being used in the judicial domain for determination of paternity, often associated with child support claims, and for forensic purposes in cases where DNA material is available for testing.

9. Plant Breeding: Genetic Methods

The cultivation of plants is the world’s oldest biotechnology. We have continually tried to produce improved varieties while increasing yield, features to aid cultivation and harvesting, disease, and pest resistance, or crop qualities such as longer postharvest storage life and improved taste or nutritional value. Early changes resulted from random crosspollination, rudimentary grafting, or spontaneous genetic change. For centuries, man kept the seed from the plants with improved characteristics to plant the following season’s crop. The pioneering work of Gregor Mendel and his development of the basic laws of heredity showed for other first time that some of the processes of heredity could be altered by experimental means. The genetic analysis of bacterial (prokaryote) genes and techniques for analysis of the higher (eukaryotic) organisms such as plants developed in parallel streams, but the rediscovery of Mendel’s work in 1900 fueled a burst of activity on understanding the role of genes in inheritance. The knowledge that genes are linked along the chromosome thereby allowed mapping of genes (transduction analysis, conjugation analysis, and transformation analysis). The power of genetics to produce a desirable plant was established, and it was appreciated that controlled breeding (test crosses and back crosses) and careful analysis of the progeny could distinguish traits that were dominant or recessive, and establish pure breeding lines. Traditional horticultural techniques of artificial self-pollination and cross-pollination were also used to produce hybrids. In the 1930s the Russian Nikolai Vavilov recognized the value of genetic diversity in domesticated crop plants and their wild relatives to crop improvement, and collected seeds from the wild to study total genetic diversity and use these in breeding programs. The impact of scientific crop breeding was established by the ‘‘Green revolution’’ of the 1960s, when new wheat varieties with higher yields were developed by careful crop breeding. ‘‘Mutation breeding’’— inducing mutations by exposing seeds to x-rays or chemicals such as sodium azide, accelerated after World War II. It was also discovered that plant cells and tissues grown in tissue culture would mutate rapidly. In the 1970s, haploid breeding, which involves producing plants from two identical sets of chromosomes, was extensively used to create new cultivars. In the twenty-first century, haploid breeding could speed up plant breeding by shortening the breeding cycle.

10. Tissue Culturing

The technique of tissue or cell culture, which relates to the growth of tissue or cells within a laboratory setting, underlies a phenomenal proportion of biomedical research. Though it has roots in the late nineteenth century, when numerous scientists tried to grow samples in alien environments, cell culture is credited as truly beginning with the first concrete evidence of successful growth in vitro, demonstrated by Johns Hopkins University embryologist Ross Harrison in 1907. Harrison took sections of spinal cord from a frog embryo, placed them on a glass cover slip and bathed the tissue in a nutrient media. The results of the experiment were startling—for the first time scientists visualized actual nerve growth as it would happen in a living organism—and many other scientists across the U.S. and Europe took up culture techniques. Rather unwittingly, for he was merely trying to settle a professional dispute regarding the origin of nerve fibers, Harrison fashioned a research tool that has since been designated by many as the greatest advance in medical science since the invention of the microscope.

From the 1980s, cell culture has once again been brought to the forefront of cancer research in the isolation and identification of numerous cancer causing oncogenes. In addition, cell culturing continues to play a crucial role in fields such as cytology, embryology, radiology, and molecular genetics. In the future, its relevance to direct clinical treatment might be further increased by the growth in culture of stem cells and tissue replacement therapies that can be tailored for a particular individual. Indeed, as cell culture approaches its centenary, it appears that its importance to scientific, medical, and commercial research the world over will only increase in the twenty-first century.

History of Biotechnology

Biotechnology grew out of the technology of fermentation, which was called zymotechnology. This was different from the ancient craft of brewing because of its thought-out relationships to science. These were most famously conceptualized by the Prussian chemist Georg Ernst Stahl (1659–1734) in his 1697 treatise Zymotechnia Fundamentalis, in which he introduced the term zymotechnology. Carl Balling, long-serving professor in Prague, the world center of brewing, drew on the work of Stahl when he published his Bericht uber die Fortschritte der zymotechnische Wissenschaften und Gewerbe (Account of the Progress of the Zymotechnic Sciences and Arts) in the mid-nineteenth century. He used the idea of zymotechnics to compete with his German contemporary Justus Liebig for whom chemistry was the underpinning of all processes.

By the end of the nineteenth century, there were attempts to develop a new scientific study of fermentation. It was an aspect of the ‘‘second’’ Industrial Revolution during the period from 1870 to 1914. The emergence of the chemical industry is widely taken as emblematic of the formal research and development taking place at the time. The development of microbiological industries is another example. For the first time, Louis Pasteur’s germ theory made it possible to provide convincing explanations of brewing and other fermentation processes.

Pasteur had published on brewing in the wake of France’s humiliation in the Franco–Prussian war (1870–1871) to assert his country’s superiority in an industry traditionally associated with Germany. Yet the science and technology of fermentation had a wide range of applications including the manufacture of foods (cheese, yogurt, wine, vinegar, and tea), of commodities (tobacco and leather), and of chemicals (lactic acid, citric acid, and the enzyme takaminase). The concept of zymotechnology associated principally with the brewing of beer began to appear too limited to its principal exponents. At the time, Denmark was the world leader in creating high-value agricultural produce. Cooperative farms pioneered intensive pig fattening as well as the mass production of bacon, butter, and beer. It was here that the systems of science and technology were integrated and reintegrated, conceptualized and reconceptualized.

The Dane Emil Christian Hansen discovered that infection from wild yeasts was responsible for numerous failed brews. His contemporary Alfred Jørgensen, a Copenhagen consultant closely associated with the Tuborg brewery, published a widely used textbook on zymotechnology. Microorganisms and Fermentation first appeared in Danish 1889 and would be translated, reedited, and reissued for the next 60 years.

The scarcity of resources on both sides during World War I brought together science and technology, further development of zymotechnology, and formulation of the concept of biotechnology. Impending and then actual war accelerated the use of fermentation technologies to make strategic materials. In Britain a variant of a process to ferment starch to make butadiene for synthetic rubber production was adapted to make acetone needed in the manufacture of explosives. The process was technically important as the first industrial sterile fermentation and was strategically important for munitions supplies. The developer, chemist Chaim Weizmann, later became well known as the first president of Israel in 1949.

In Germany scarce oil-based lubricants were replaced by glycerol made by fermentation. Animal feed was derived from yeast grown with the aid of the new synthetic ammonia in another wartime development that inspired the coining of the word biotechnology. Hungary was the agricultural base of the Austro–Hungarian empire and aspired to Danish levels of efficiency. The economist Karl Ereky (1878–1952) planned to go further and build the largest industrial pig-processing factory. He envisioned a site that would fatten 50,000 swine at a time while railroad cars of sugar beet arrived and fat, hides, and meat departed. In this forerunner of the Soviet collective farm, peasants (in any case now falling prey to the temptations of urban society) would be completely superseded by the industrialization of the biological process in large factory-like animal processing units. Ereky went further in his ruminations over the meaning of his innovation. He suggested that it presaged an industrial revolution that would follow the transformation of chemical technology. In his book entitled Biotechnologie, he linked specific technical injunctions to wide-ranging philosophy. Ereky was neither isolated nor obscure. He had been trained in the mainstream of reflection on the meaning of the applied sciences in Hungary, which would be remarkably productive across the sciences. After World War I, Ereky served as Hungary’s minister of food in the short-lived right wing regime that succeeded the fall of the communist government of Bela Kun.

Nonetheless it was not through Ereky’s direct action that his ideas seem to have spread. Rather, his book was reviewed by the influential Paul Lindner, head of botany at the Institut fu¨ r Ga¨ rungsgewerbe in Berlin, who suggested that microorganisms could also be seen as biotechnological machines. This concept was already found in the production of yeast and in Weizmann’s work with strategic materials, which was widely publicized at that very time. It was with this meaning that the word ‘‘Biotechnologie’’ entered German dictionaries in the 1920s.

Biotechnology represented more than the manipulation of existing organisms. From the beginning it was concerned with their improvement as well, and this meant the enhancement of all living creatures. Most dramatically this would include humanity itself; more mundanely it would include plants and animals of agricultural importance. The enhancement of people was called eugenics by the Victorian polymath and cousin of Charles Darwin, Francis Galton. Two strains of eugenics emerged: negative eugenics associated with weeding out the weak and positive eugenics associated with enhancing strength. In the early twentieth century, many eugenics proponents believed that the weak could be made strong. People had after all progressed beyond their biological limits by means of technology.

Jean-Jacques Virey, a follower of the French naturalist Jean-Baptiste de Monet de Lamarck, had coined the term ‘‘biotechnie’’ in 1828 to describe man’s ability to make technology do the work of biology, but it was not till a century later that the term entered widespread use. The Scottish biologist and town planner Patrick Geddes made biotechnics popular in the English-speaking world. Geddes, too, sought to link life and technology. Before World War I he had characterized the technological evolution of mankind as a move from the paleotechnic era of coal and iron to the neotechnic era of chemicals, electricity, and steel. After the war, he detected a new era based on biology—the biotechnic era. Through his friend, writer Lewis Mumford, Geddes would have great influence. Mumford’s book Technics and Civilization, itself a founding volume of the modern historiography of technology, promoted his vision of the Geddesian evolution.

A younger generation of English experimental biologists with a special interest in genetics, including J. B. S. Haldane, Julian Huxley, and Lancelot Hogben, also promoted a concept of biotechnology in the period between the world wars. Because they wrote popular works, they were among Britain’s best-known scientists. Haldane wrote about biological invention in his far-seeing work Daedalus. Huxley looked forward to a blend of social and eugenics-based biological engineering. Hogben, following Geddes, was more interested in engineering plants through breeding. He tied the progressivism of biology to the advance of socialism.

The improvement of the human race, genetic manipulation of bacteria, and the development of fermentation technology were brought together by the development of penicillin during World War II. This drug was successfully extracted from the juice exuded by a strain of the Penicillium fungus. Although discovered by accident and then developed further for purely scientific reasons, the scarce and unstable ‘‘antibiotic’’ called penicillin was transformed during World War II into a powerful and widely used drug. Large networks of academic and government laboratories and pharmaceutical manufacturers in Britain and the U.S. were coordinated by agencies of the two governments. An unanticipated combination of genetics, biochemistry, chemistry, and chemical engineering skills had been required. When the natural mold was bombarded with high-frequency radiation, far more productive mutants were produced, and subsequently all the medicine was made using the product of these man-made cells. By the 1950s penicillin was cheap to produce and globally available.

The new technology of cultivating and processing large quantities of microorganisms led to calls for a new scientific discipline. Biochemical engineering was one term, and applied microbiology another. The Swedish biologist, Carl-Goran Heden, possibly influenced by German precedents, favored the term ‘‘Biotechnologi’’ and persuaded his friend Elmer Gaden to relabel his new journal Biotechnology and Biochemical Engineering. From 1962 major international conferences were held under the banner of the Global Impact of Applied Microbiology. During the 1960s food based on single-cell protein grown in fermenters on oil or glucose seemed, to visionary engineers and microbiologists and to major companies, to offer an immediate solution to world hunger. Tropical countries rich in biomass that could be used as raw material for fermentation were also the world’s poorest. Alcohol could be manufactured by fermenting such starch or sugar rich crops as sugar cane and corn. Brazil introduced a national program of replacing oil-based petrol with alcohol in the 1970s.

It was not, however, just the developing countries that hoped to benefit. The Soviet Union developed fermentation-based protein as a major source of animal feed through the 1980s. In the U.S. it seemed that oil from surplus corn would solve the problem of low farm prices aggravated by the country’s boycott of the USSR in1979, and the term ‘‘gasohol‘‘ came into currency. Above all, the decline of established industries made the discovery of a new wealth maker an urgent priority for Western governments. Policy makers in both Germany and Japan during the 1970s were driven by a sense of the inadequacy of the last generation of technologies. These were apparently maturing, and the succession was far from clear. Even if electronics or space travel offered routes to the bright industrial future, these fields seemed to be dominated by the U.S. Seeing incipient crisis, the Green, or environmental, movement promoted a technology that would depend on renewable resources and on low-energy processes that would produce biodegradable products, recycle waste, and address problems of the health and nutrition of the world.

In 1973 the German government, seeking a new and ‘‘greener’’ industrial policy, commissioned a report entitled Biotechnologie that identified ways in which biological processing was key to modern developments in technology. Even though the report was published at the time that recombinant DNA (deoxyribonucleic acid) was becoming possible, it did not refer to this new technique and instead focused on the use and combination of existing technologies to make novel products.

Nonetheless the hitherto esoteric science of molecular biology was making considerable progress, although its practice in the early 1970s was rather distant from the world of industrial production. The phrase ‘‘genetic engineering’’ entered common parlance in the 1960s to describe human genetic modification. Medicine, however, put a premium on the use of proteins that were difficult to extract from people: insulin for diabetics and interferon for cancer sufferers. During the early 1970s what had been science fiction became fact as the use of DNA synthesis, restriction enzymes, and plasmids were integrated. In 1973 Stanley Cohen and Herbert Boyer successfully transferred a section of DNA from one E. coli bacterium to another. A few prophets such as Joshua Lederberg and Walter Gilbert argued that the new biological techniques of recombinant DNA might be ideal for making synthetic versions of expensive proteins such as insulin and interferon through their expression in bacterial cells. Small companies, such as Cetus and Genentech in California and Biogen in Cambridge, Massachusetts, were established to develop the techniques. In many cases discoveries made by small ‘‘boutique’’ companies were developed for the market by large, more established, pharmaceutical organizations.

Many governments were impressed by these advances in molecular genetics, which seemed to make biotechnology a potential counterpart to information technology in a third industrial revolution. These inspired hopes of industrial production of proteins identical to those produced in the human body that could be used to treat genetic diseases. There was also hope that industrially useful materials such as alcohol, plastics (biopolymers), or ready-colored fibers might be made in plants, and thus the attractions of a potentially new agricultural era might be as great as the implications for medicine. At a time of concern over low agricultural prices, such hopes were doubly welcome. Indeed, the agricultural benefits sometimes overshadowed the medical implications.

The mechanism for the transfer of enthusiasm from engineering fermenters to engineering genes was the New York Stock Exchange. At the end of the 1970s, new tax laws encouraged already adventurous U.S. investors to put money into small companies whose stock value might grow faster than their profits. The brokerage firm E. F. Hutton saw the potential for the new molecular biology companies such as Biogen and Cetus. Stock market interest in companies promising to make new biological entities was spurred by the 1980 decision of the U.S. Supreme Court to permit the patenting of a new organism. The patent was awarded to the Exxon researcher Ananda Chakrabarty for an organism that metabolized hydrocarbon waste. This event signaled the commercial potential of biotechnology to business and governments around the world. By the early 1980s there were widespread hopes that the protein interferon, made with some novel organism, would provide a cure for cancer. The development of monoclonal antibody technology that grew out of the work of Georges J. F. Kohler and Cesar Milstein in Cambridge (co-recipients with Niels K. Jerne of the Nobel Prize in medicine in 1986) seemed to offer new prospects for precise attacks on particular cells.

The fear of excessive regulatory controls encouraged business and scientific leaders to express optimistic projections about the potential of biotechnology. The early days of biotechnology were fired by hopes of medical products and high-value pharmaceuticals. Human insulin and interferon were early products, and a second generation included the anti-blood clotting agent tPA and the antianemia drug erythropoietin. Biotechnology was also used to help identify potential new drugs that might be made chemically, or synthetically.

At the same time agricultural products were also being developed. Three early products that each raised substantial problems were bacteria which inhibited the formation of frost on the leaves of strawberry plants (ice-minus bacteria), genetically modified plants including tomatoes and rapeseed, and the hormone bovine somatrotropin (BST) produced in genetically modified bacteria and administered to cattle in the U.S. to increase milk yields. By 1999 half the soy beans and one third of the corn grown in the U.S. were modified. Although the global spread of such products would arouse the best known concern at the end of the century, the use of the ice-minus bacteria— the first authorized release of a genetically engineered organism into the environment—had previously raised anxiety in the U.S. in the 1980s.

In 1997 Dolly the sheep was cloned from an adult mother in the Roslin agricultural research institute outside Edinburgh, Scotland. This work was inspired by the need to find a way of reproducing sheep engineered to express human proteins in their milk. However, the public interest was not so much in the cloning of sheep that had just been achieved as in the cloning of people, which had not. As in the Middle Ages when deformed creatures had been seen as monsters and portents of natural disasters, Dolly was similarly seen as monster and as a portent of human cloning.

The name Frankenstein, recalled from the story written by Mary Shelley at the beginning of the nineteenth century and from the movies of the 1930s, was once again familiar at the end of the twentieth century. Shelley had written in the shadow of Stahl’s theories. The continued appeal of this book embodies the continuity of the fears of artificial life and the anxiety over hubris. To this has been linked a more mundane suspicion of the blending of commerce and the exploitation of life. Discussion of biotechnology at the end of the twentieth century was therefore colored by questions of whose assurances of good intent and reassurance of safety could be trusted.

Browse other Technology Research Paper Topics .

ORDER HIGH QUALITY CUSTOM PAPER

• Interesting
• Scholarships
• UGC-CARE Journals

Top 50 Emerging Research Topics in Biotechnology

Trending Research Topics in Biotechnology

Table of contents

A. crispr and gene editing, b. synthetic biology, a. precision medicine, b. pharmacogenomics, a. nanoparticles in medicine, b. nanosensors and diagnostics, a. cancer immunotherapy, b. vaccine technology, a. bioremediation and bioenergy, b. agricultural biotechnology.

Biotechnology is a dynamic field that continuously shapes our world, enabling innovation, breakthroughs, and solutions to various challenges. As we move into the future, numerous emerging research areas promise to revolutionize healthcare, agriculture, environmental sustainability, and more. The top 50 emerging research topics in biotechnology are presented in this article.

1. Gene Editing and Genomic Engineering

Precision Medicine : Developing targeted therapies for various diseases using CRISPR/Cas9 and other gene-editing tools.

Ethical Implications : Exploring and addressing ethical concerns surrounding CRISPR use in human embryos and germline editing.

Agricultural Advancements : Enhancing crop resistance and nutritional content through gene editing of improved farm outcomes.

Gene Drive Technology : Investigating the potential of gene drive technology to control vector-borne diseases like malaria and dengue fever.

Regulatory Frameworks : Establishing global regulations for responsible gene editing applications in different fields.

Bioengineering Microbes : Creating engineered microorganisms for sustainable production of fuels, pharmaceuticals, and materials.

Designer Organisms : Designing novel organisms with specific functionalities for environmental remediation or industrial processes.

Cell-Free Systems : Developing cell-free systems for various applications, including drug production and biosensors.

Biosecurity Measures : Addressing concerns regarding the potential misuse of synthetic biology for bioterrorism.

Standardization and Automation : Standardizing synthetic biology methodologies and automating processes to streamline production.

2. Personalized Medicine and Pharmacogenomics

Individualized Treatment : Tailoring medical treatment based on a person’s genetic makeup and environmental factors.

Cancer Therapy : Advancing targeted cancer therapies based on the genetic profile of tumors and patients.

Data Analytics : Implementing big data and AI for comprehensive analysis of genomic and clinical data to improve treatment outcomes.

Clinical Implementation : Integrating genetic testing into routine clinical practice for personalized healthcare.

Public Health and Policy : Addressing the challenges of integrating personalized medicine into public health policies and practices.

Drug Development : Optimizing drug development based on individual genetic variations to improve efficacy and reduce side effects.

Adverse Drug Reactions : Understanding genetic predispositions to adverse drug reactions and minimizing risks.

Dosing Optimization : Tailoring drug dosage based on an individual’s genetic profile for better treatment outcomes.

Economic Implications : Assessing the economic impact of pharmacogenomics on healthcare systems.

Education and Training : Educating healthcare professionals on integrating pharmacogenomic data into clinical practice.

3. Nanobiotechnology and Nanomedicine

Drug Delivery Systems : Developing targeted drug delivery systems using nanoparticles for enhanced efficacy and reduced side effects.

Theranostics : Integrating diagnostics and therapeutics through nanomaterials for personalized medicine.

Imaging Techniques : Advancing imaging technologies using nanoparticles for better resolution and early disease detection.

Biocompatibility and Safety : Ensuring the safety and biocompatibility of nanoparticles used in medicine.

Regulatory Frameworks : Establishing regulations for the use of nanomaterials in medical applications.

Point-of-Care Diagnostics : Developing portable and rapid diagnostic tools for various diseases using nanotechnology.

Biosensors : Creating highly sensitive biosensors for detecting biomarkers and pathogens in healthcare and environmental monitoring.

Wearable Health Monitors : Integrating nanosensors into wearable devices for continuous health monitoring.

Challenges and Limitations : Addressing challenges in scalability, reproducibility, and cost-effectiveness of nanosensor technologies.

Future Applications : Exploring potential applications of nanosensors beyond healthcare, such as environmental monitoring and food safety.

4. Immunotherapy and Vaccine Development

Immune Checkpoint Inhibitors : Enhancing the efficacy of immune checkpoint inhibitors and understanding resistance mechanisms.

CAR-T Cell Therapy : Improving CAR-T cell therapy for a wider range of cancers and reducing associated side effects.

Combination Therapies : Investigating combination therapies for better outcomes in cancer treatment.

Biomarkers and Predictive Models : Identifying predictive biomarkers for immunotherapy response.

Long-Term Effects : Studying the long-term effects and immune-related adverse events of immunotherapies.

mRNA Vaccines : Advancing mRNA vaccine technology for various infectious diseases and cancers.

Universal Vaccines : Developing universal vaccines targeting multiple strains of viruses and bacteria.

Vaccine Delivery Systems : Innovating vaccine delivery methods for improved stability and efficacy.

Vaccine Hesitancy : Addressing vaccine hesitancy through education, communication, and community engagement.

Pandemic Preparedness : Developing strategies for rapid vaccine development and deployment during global health crises.

5. Environmental Biotechnology and Sustainability

Biodegradation Techniques : Using biotechnology to enhance the degradation of pollutants and contaminants in the environment.

Biofuels : Developing sustainable biofuel production methods from renewable resources.

Microbial Fuel Cells : Harnessing microbial fuel cells for energy generation from organic waste.

Circular Economy : Integrating biotechnological solutions for a circular economy and waste management.

Ecosystem Restoration : Using biotechnology for the restoration of ecosystems affected by pollution and climate change.

Genetically Modified Crops : Advancing genetically modified crops for improved yields, pest resistance, and nutritional content.

Precision Agriculture : Implementing biotechnological tools for precise and sustainable farming practices.

Climate-Resilient Crops : Developing crops resilient to climate change-induced stresses.

Micro-biome Applications : Leveraging the plant micro-biome for enhanced crop health and productivity.

Consumer Acceptance and Regulation : Addressing consumer concerns and regulatory challenges related to genetically modified crops.

The field of biotechnology is a beacon of hope for addressing the challenges of our time, offering promising solutions for healthcare, sustainability, and more. As researchers explore these emerging topics, the potential for ground-breaking discoveries and transformative applications is immense.

I hope this article will help you to find the top research topics in biotechnology that promise to revolutionize healthcare, agriculture, environmental sustainability, and more.

• Drug delivery
• Environmental Engineering
• Gene editing
• Genomic Engineering
• Molecular Biology
• Nanoparticles
• Pharmacogenomics
• Research Ideas
• Synthetic biology

What is Research Design? and How to Frame it?

42 digital signal processing project ideas to explore, what is a research design importance and types, email subscription.

iLovePhD is a research education website to know updated research-related information. It helps researchers to find top journals for publishing research articles and get an easy manual for research tools. The main aim of this website is to help Ph.D. scholars who are working in various domains to get more valuable ideas to carry out their research. Learn the current groundbreaking research activities around the world, love the process of getting a Ph.D.

WhatsApp Channel

Join iLovePhD WhatsApp Channel Now!

Contact us: [email protected]

Copyright © 2019-2024 - iLovePhD

• Artificial intelligence

Hot Research Topics in Biotech in 2022

The past few years years have seen leaps and strides of innovation as scientists have worked to develop and produce new mRNA vaccinations and made major developments in biotech research. During this time, they’ve also faced challenges. Ongoing supply chain disruptions , the Great Resignation, and the pandemic have impacted biotech labs and researchers greatly, forcing lab managers and PIs to get creative with lab supply purchasing, experiment planning, and the use of technology in order to maintain their research schedules.

“The pace of innovation specific to COVID to be able to develop both medicines related to antibodies as well as vaccines is just staggering. Those of us in the industry are in awe of the innovation we’re witnessing on a daily basis. We’ve been behind in the use of automation, software, and AI that can make our industry more efficient — that’s where we’re headed,” says Michelle Dipp, Cofounder and Managing Partner, Biospring Partners on the This is ZAGENO podcast .

At the start of 2022, current biotech research projects are exploring advancements in medicine, vaccines, the human body and treatment of disease, bacteria and immunology, and viruses like the Coronavirus that affected the globe in ways we couldn’t have anticipated.

Biotech Research Processes are Changing

As Michelle explained, the research that’s happening is changing, and so is the way that scientists conduct it. Influenced by both B2C ecommerce and the growing dependence on remote and cloud-based working, biotech labs are undergoing digital transformations . This means more software, AI, and automation in the lab, along with modern digital procurement strategies and integrated systems for lab operations.

Here are some of the top biotech research trends and recent biotech research papers that are changing the world of science and leading to innovation in life sciences.

Top 6 Biotech Research Topics for 2022

Science journals have never been more popular as they’ve been in the past several years. Resonating with the general public, biotech research papers have found their way into the hands and social media streams of interested citizens and scientists alike.

As we look to the most credible, peer-reviewed sources for recent innovations like PubMed , the Journal of Biotechnology , BioTech , and Biotechnology Journal , the trending themes in biotech research are in direct response to COVID-19, like vaccine development, respiratory virus research, and RNA-based pharmaceuticals. Additionally, there have been major advances in metabolism and the human microbiome, as well as further exploration in microvesicles.

All of the research happening has the potential to change millions of people’s quality of life, prevent and treat illnesses that currently have high mortality rates, and change healthcare around the world.

Here's what's happening in biotech research.

1. Vaccine Development mRNA vaccine development has been in the works since 1989 and was accelerated in recent years to combat the global COVID-19 pandemic. Researchers like Maruggi, Zhang, Li, Ulmer, Yu and their team believe that mRNA vaccines could change infectious disease control as we know it as a prophylactic means of disease prevention for diseases like HIV, Zika, and the flu.

Recent developments in mRNA research from Pardi, Hogan, and Weissman in 2020 explored the ways that mRNA vaccines can combat certain cancers and infectious pathogens that were previously resistant to existing vaccine options.

With new access to data from the 3.4 billion+ COVID-19 mRNA vaccines that have been administered worldwide, researchers have been able to determine the risks associated with mRNA vaccines , which brings forward new topics for research in the medical and pharmaceutical sides of the biotech industry. mRNA vaccines are faster to develop and can help prevent more diseases than traditional vaccine methods.

2. Respiratory Viruses Acute respiratory diseases (ARDs) like those caused by the SARS-CoV pathogen or the influenza virus lead to morbidity and mortality, and can lead to pneumonia, which can be fatal for immunocompromised or elderly patients — they represent a huge impact to human society.

Identifying the cause of ARDs and identifying viral infections from COVID-19 has become an issue of public health and safety, leading research groups like Zhang, Wang, and team to seek out more accurate and faster ways to detect respiratory viruses .

Understanding these respiratory virus mechanisms can help lead to better protection, prevention, and treatments for respiratory viruses, which have a mortality rate of up to 78% .

3. RNA-based Therapeutics RNA-based treatments like modified non-coding RNAs (ncRNAs), microRNAs (miRNAs), and others have been developed and studied by teams like Feng, Patil, et al (2021) to treat various diseases and conditions, including pancreatic cancer, acute renal failure, acute kidney injuries, diabetic macular edema, and advanced solid tumors.

In 2022, we expect to see further development of RNA-based therapeutics, like CAR T cells and other gene/cell therapeutics, therapeutic antibodies, and small molecular drugs to treat even more diseases and for prophylactic purposes as well.

4. Microvesicles + Extracellular Vesicles Microvesicles are coming to light due to their involvement in transporting mRNA, miRNA, and proteins — but how else might they support the human body? There are unknown functions of microvesicles and other extracellular vesicles that have yet to be discovered.

In 2020, Ratajczak and Ratajczak found that understanding microvesicles (or exosomes, microparticles) could mean understanding cell-to-cell communication , and their research showed that extracellular vesicles could transfer mRNA and proteins and modify stem cells ex vivo. This year, we look forward to seeing more research on what these tiny cell parts can do.

5. Metabolism in Cancers + Other Diseases Metabolism is the process of energy conversion in organisms and it represents the chemical reactions that sustain life. Recent research on metabolism in cancers and in immune cells has uncovered new ways to approach treatment and prevention of certain illnesses.

Take a look at Matsushita, Nakagawa, and Koike’s (2021) research on lipid metabolism in oncology and how recent advances in lipidomics technology and mass spectrometry have opened the door for new analysis of lipid profiles of certain cancers.

6. The Human Microbiome The human microbiome hosts bacteria, microorganisms, and other naturally-occurring flora that can help us and harm us. Diet, stress, drugs, and other factors shape the microbiome, leading to inflammation and an immune response of cytokines. Recent machine learning and statistical analyses of microbiome data , like that of Indias, Lahti, Nedyalkova, and team (2021) are getting smarter and smarter by removing variables and providing ways to test new hypotheses using statistical modeling.

With a deeper understanding of the microbiome, researchers like David Sinclair have shown that lifestyle changes can actually help people live healthier lives for longer . Sinclair’s lab is at the forefront of aging research and its impact on healthcare — and it’s all rooted in biotechnology and life science experiments.

Recent updates to ICD-11 and its classification of aging as a disease have led to debate, with Sinclair and colleagues advocating for the ongoing paradigm shift that biological age and chronological age are not synonymous. The implications for longevity and aging research from a funding perspective will be impacted by WHO and NIH decisions, and we anticipate seeing more biotech research on topics like epigenetics, metabolism, mitochondrial dysfunction, reproduction, and stem cell developments in the coming years.

Biotech research can change humankind, and lead to a better quality of life for generations to come. Subscribe to the ZAGENO blog to keep up with the latest topics in biotech and life sciences research and find the tech that supports biotech lab managers and PIs in their ongoing work.

To learn more about how ZAGENO can eliminate the lab management challenges, gain access.

Related Posts

3 Supplier Diversification Pro-Tips for a Cost-Effective, Resilient Lab Supply Chain

The AI-powered lab supply marketplace: How AI is improving the customer buying journey

2024 Lab Supply Pricing Trend Insights

If you're seeing this message, it means we're having trouble loading external resources on our website.

If you're behind a web filter, please make sure that the domains *.kastatic.org and *.kasandbox.org are unblocked.

To log in and use all the features of Khan Academy, please enable JavaScript in your browser.

AP®︎/College Biology

Course: ap®︎/college biology   >   unit 6.

• Introduction to genetic engineering

Intro to biotechnology

• DNA cloning and recombinant DNA
• Overview: DNA cloning
• Polymerase chain reaction (PCR)
• Gel electrophoresis
• DNA sequencing
• Applications of DNA technologies
• Biotechnology

Key points:

• Biotechnology is the use of an organism, or a component of an organism or other biological system, to make a product or process.
• Many forms of modern biotechnology rely on DNA technology.
• DNA technology is the sequencing, analysis, and cutting-and-pasting of DNA.
• Common forms of DNA technology include DNA sequencing , polymerase chain reaction , DNA cloning , and gel electrophoresis .
• Biotechnology inventions can raise new practical concerns and ethical questions that must be addressed with informed input from all of society.

Introduction

What is biotechnology.

• Beer brewing . In beer brewing, tiny fungi (yeasts) are introduced into a solution of malted barley sugar, which they busily metabolize through a process called fermentation. The by-product of the fermentation is the alcohol that’s found in beer. Here, we see an organism – the yeast – being used to make a product for human consumption.
• Penicillin. The antibiotic penicillin is generated by certain molds. To make small amounts of penicillin for use in early clinical trials, researchers had to grow up to 500 ‍   liters of “mold juice” a week 1 ‍   . The process has since been improved for industrial production, with use of higher-producing mold strains and better culture conditions to increase yield 2 ‍   . Here, we see an organism (mold) being used to make a product for human use – in this case, an antibiotic to treat bacterial infections.
• Gene therapy. Gene therapy is an emerging technique used to treat genetic disorders that are caused by a nonfunctional gene. It works by delivering the “missing” gene’s DNA to the cells of the body. For instance, in the genetic disorder cystic fibrosis, people lack function of a gene for a chloride channel produced in the lungs. In a recent gene therapy clinical trial, a copy of the functional gene was inserted into a circular DNA molecule called a plasmid and delivered to patients’ lung cells in spheres of membrane (in the form of a spray) 3 ‍   . In this example, biological components from different sources (a gene from humans, a plasmid originally from bacteria) were combined to make a new product that helped preserve lung function in cystic fibrosis patients.

What is DNA technology?

Examples of dna technologies.

• DNA cloning. In DNA cloning , researchers “clone” – make many copies of – a DNA fragment of interest, such as a gene. In many cases, DNA cloning involves inserting a target gene into a circular DNA molecule called a plasmid. The plasmid can be replicated in bacteria, making many copies of the gene of interest. In some cases, the gene is also expressed in the bacteria, making a protein (such as the insulin used by diabetics). Insertion of a gene into a plasmid.
• Polymerase chain reaction (PCR). Polymerase chain reaction is another widely used DNA manipulation technique, one with applications in almost every area of modern biology. PCR reactions produce many copies of a target DNA sequence starting from a piece of template DNA. This technique can be used to make many copies of DNA that is present in trace amounts (e.g., in a droplet of blood at a crime scene).
• Gel electrophoresis. Gel electrophoresis is a technique used to visualize (directly see) DNA fragments. For instance, researchers can analyze the results of a PCR reaction by examining the DNA fragments it produces on a gel. Gel electrophoresis separates DNA fragments based on their size, and the fragments are stained with a dye so the researcher can see them. DNA fragments migrate through the gel from the negative to the positive electrode. After the gel has run, the fragments are separated by size, with the smallest ones near the bottom (positive electrode) and the largest ones near the top (negative electrode). Based on similar diagram in Reece et al. 5 ‍  
• DNA sequencing. DNA sequencing involves determining the sequence of nucleotide bases (As, Ts, Cs, and Gs) in a DNA molecule. In some cases, just one piece of DNA is sequenced at a time, while in other cases, a large collection of DNA fragments (such as those from an entire genome) may be sequenced as a group. What is a genome? A genome refers to all of an organism's DNA. In eukaryotes, which have a nucleus in their cells to hold their DNA, the word genome is usually used for the nuclear genome (DNA found in the nucleus), excluding the DNA found in organelles such as chloroplasts or mitochondria.

Biotechnology raises new ethical questions

• Some of these relate to privacy and non-discrimination. For instance should your health insurance company be able to charge you more if you have a gene variant that makes you likely to develop a disease? How would you feel if your school or employer had access to your genome?
• Other questions relate to the safety, health effects, or ecological impacts of biotechnologies. For example, crops genetically engineered to make their own insecticide reduce the need for chemical spraying, but also raise concerns about plants escaping into the wild or interbreeding with local populations (potentially causing unintended ecological consequences).
• Biotechnology may provide knowledge that creates hard dilemmas for individuals. For example, a couple may learn via prenatal testing that their fetus has a genetic disorder. Similarly, a person who has her genome sequenced for the sake of curiosity may learn that she is going to develop an incurable, late-onset genetic disease, such as Huntington's.

Educate yourself and share your perspective

Works cited:.

• American Chemical Society. (2016). Discovery and development of penicillin. In Chemical landmarks . Retrieved from http://www.acs.org/content/acs/en/education/whatischemistry/landmarks/flemingpenicillin.html .
• Meštrović, T. and Chow, S. (2015, April 29). Penicillin production. In News medical . Retrieved from http://www.news-medical.net/health/Penicillin-Production.aspx .
• Alton, E. W. F. W., Armstrong, D. K., Ashby, D., Bayfield, K. J., Bilton, Diana, Bloomfield, E. V., ... Wolstenholme-Hogg, P. (2015). Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: A randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine , 3 (9), 684-691. http://dx.doi.org/10.1016/S2213-2600(15)00245-3 .
• Reece, J. B., Urry, L. A., Cain, M. L., Wasserman, S. A., Minorsky, P. V., and Jackson, R. B. (2011). The DNA toolbox. In Campbell biology (10th ed., pp. 408-409). San Francisco, CA: Pearson.
• Reece, J. B., Taylor, M. R., Simon, E. J., and Dickey, J. L. (2012). Figure 12.13. Gel electrophoresis of DNA. In Campbell biology: Concepts & connections (7th ed., p. 243).

Additional references:

Want to join the conversation.

• Upvote Button navigates to signup page
• Downvote Button navigates to signup page
• Flag Button navigates to signup page

• Search Menu
• FEMS Microbiology Ecology
• FEMS Microbiology Letters
• FEMS Microbiology Reviews
• FEMS Yeast Research
• Pathogens and Disease
• FEMS Microbes
• Awards & Prizes
• Editor's Choice Articles
• Thematic Issues
• Virtual Special Issues
• Call for Papers
• Journal Policies
• Open Access Options
• Submit to the FEMS Journals
• Why Publish with the FEMS Journals
• About the Federation of European Microbiological Societies
• About the FEMS Journals
• Advertising and Corporate Services
• Conference Reports
• Editorial Boards
• Investing in Science
• Journals Career Network
• Journals on Oxford Academic
• Books on Oxford Academic

Six Key Topics in Microbiology: 2024

This collection from the FEMS journals presents the latest high-quality research in six key topic areas of microbiology that have an impact across the world. All of the FEMS journals aim to serve the microbiology community with timely and authoritative research and reviews, and by investing back into the science community . 

Interested in publishing your research relevant to the six key microbiology topics?

Learn more about why the FEMS journals are the perfect home for your microbiology research.  

Browse the collection categories: 

Antimicrobial resistance, environmental microbiology, pathogenicity and virulence, biotechnology and synthetic biology, microbiomes, food microbiology.

FEMS and Open Access: Embracing an Open Future

As of January 2024, FEMS has flipped four of its journals to fully open access (OA), making six out of its seven journals OA. FEMS Microbiology Letters remains a subscription journal and free to publish in. 

We are excited to be making high quality science freely available to anyone to read anywhere in the world and further supporting the advancement of our discipline. 

View our FAQs page

Never miss the latest research from the FEMS Journals

Stay up to date on the latest microbiology research with content alerts delivered directly to your inbox. This free service  from OUP allows you to create custom email alerts to make sure you never miss our on the latest research from your favorite FEMS journals. 

Learn more & sign up

Latest posts on X

Affiliations.

• Copyright © 2024
• About Oxford Academic
• Publish journals with us
• University press partners
• What we publish
• New features  
• Open access
• Institutional account management
• Rights and permissions
• Get help with access
• Accessibility
• Advertising
• Media enquiries
• Oxford University Press
• Oxford Languages
• University of Oxford

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide

• Copyright © 2024 Oxford University Press
• Cookie settings
• Cookie policy
• Privacy policy
• Legal notice

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This PDF is available to Subscribers Only

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

• Privacy Policy

Biotechnology Research Topics

What is biotechnology.

What first pops up in your mind when you hear the term Biotechnology? Maybe you started thinking of GMOs ( Genetically Modified Organisms ), transgenic cloning, and other gene therapies. Of course, you got it right, but the horizon of biotechnology is not so tiny. It has a wide range of applications in the industry that can improve our living standards. Let us first understand the term Biotechnology. In simple words, it is the utilization of living organisms or their components in the industrial sector to generate various products that are beneficial for the human race. We have been utilizing microorganisms for more than thousands of years to develop useful commodities such as cheese, bread, and various other dairy-related products. Even its implementation in the medical sector has led to the manufacturing of different vaccines, biofuel, chitosan-coated dressing for wounds, brewing, and even age-defying products. As the biotechnology scope is expanding day by day, researchers felt an urge to classify main areas and types of biotechnology depending on some commonalities and their ultimate objectives:

Red Biotechnology- involves the utilization of organisms for upgrading the quality of health care departments and aiding the body’s immune system to fight against various diseases. Examples include; the development of different vaccines, antibiotics, medicinal drugs, and various molecular techniques.

White Biotechnology- mainly comprises industrial biotechnology and involves the utilization of microorganisms and their by-products for manufacturing more eco-friendly and energy-efficient products. White biotechnology examples include the production of biofuel, Lactic acid, and 3- hydroxy propionic acid.

Yellow Biotechnology- it is related to the use of Biotech in the food production area, i.e., making bread, cheese, beer, and wine by the fermentation process.

Grey Biotechnology – mainly deals with the removal of pollutants from the environment by using various microorganisms and plants. For example., different strains of bacteria can be used for the degradation of kitchen waste into compost.

  Green Biotechnology- concentrates on the agriculture sector and focuses on generating new varieties of plants and producing good quality bio-pesticides & bio-fertilizers.

  Blue Biotechnology – it mainly refers to the utilization of aquatic or marine organisms to create goods that can aid various industrial processes, such as using Chitosan (sugar derived from the shells of crabs and shrimps) for the dressing of wounds.

Biotechnology Topics for Research Paper

In the modern world, students are apprehending the benefits of Biotech and want to study it with more enthusiasm and interest. They are actively opting for this subject and compiling their research work to contribute their efforts in the field of Biotechnology. They are indulged in exhaustive research to find the best topic for the research purpose. So, here are a few potential research topics in the domain of Biotechnology:

Red Biotechnology Research Topics:

• Studying the relationship between the intake of iron-folic acid during pregnancy and its impact on the overall health of the fetus.
• Pharmacogenomics of antimicrobial drugs.
• Identifying the biomarkers linked with breast cancer.
• Study the medicinal value of natural antioxidants.
• Study the structure of coronavirus spike proteins.
• Studying the immune response of stem cell therapy.
• Utilization of CRISPR-Cas9 technology for genome editing.
• Application of Chitosan in tissue engineering and drug delivery.
• Study the therapeutic effects of cancer vaccines.
• Utilizing PacBio sequencing for the genome assembly of model organisms.
• Study the relationship between the suppression of mRNA and its effect on stem cell expansion.
• Study the application of nanoprobes in molecular imaging.
• Incorporating biomimicry for the detection of tumor cells.
• Study of immune-based therapies in treating COVID-19.
• Regulation of immune response using the cellular and molecular mechanism
• Microchip implantation – a vaccine for coronavirus.
• The Use of CRISPR for Human Genome Editing

Yellow Biotechnology Research Topics:

• Production of hypoallergenic milk.
• Production of hypoallergenic fermented foods.
• Yellow enzymes subclassification and their characterization.

White Biotechnology Research Topics:

• Bioconversion of cellulose to yield industrially important products.
• Studying the inhibitors of endocellulase and exocellulase.
• Fungal enzymes used in the production of chemical glue.
• Mechanism of fungal enzymes in the biodegradation of lignin.
• Studying gut microbiota in model organisms.
• Study the lactic acid bacteria for probiotic potential.
• Purification of thermostable phytase.
• Mesophilic and Thermophilic aerobic and anaerobic bacteria from compost.
• Study the dietary strategies for the prophylaxis of Alzheimer’s and dementia.
• Examine the positive effects of probiotics and prebiotics on the nervous system.

Examples of Grey Biotechnology Research Topics:

• Production of sustainable, low-cost, and environmentally friendly microbial biocement and biogrouts.
• Use of microorganisms for the recovery of shale gas.
• Studying the procedure of natural decomposition.
• Treatment of grey water in a multilayer reactor with passive aeration.
• Excavation of various anaerobic microbes using grey biotechnology.
• Improving the biodegradation of micro-plastics using GMOs.
• Removal of pollutants from the land.
• Use of microbes to excavate the hidden metals from earth.
• Managing the processes of environmental biotechnology using microbial ecology.
• In situ product removal techniques using the process of biocatalysis.
• Production of biodegradable, disposable plastic for the storage of food.
• Plastic waste decomposition management.  
• Maintaining a healthy equilibrium between biotic and abiotic factors using biotechnological tools.
• Recycling of biowastes.
• Restoration of biodiversity using tools.
• Improved Recombinant DNA technology for bioremediation.
• Gold biosorption using cyanobacterium.
• Improved bioremediation of oil spills.
• Biodegradation of oil and natural gas.

Blue Biotechnology Research Ideas:

• Various bioactive compounds derived from marine sponges.
• Controlling the emerged biological contaminant using the sustainable future.
• Protecting the environment using grey, blue, and green biotechnology.  
• Exploring marine biota which survives the extreme conditions.
• Studying the patterns of Arctic and Antarctic microbiota for the benefits of humans.
• Excavation of bioactive molecules from extreme environmental conditions.
• Studying the potential of sponge-associated microbes.
• Mercury labeling in the fish using markers.
• Sea urchin repelling ocean macroalgal afforestation.
• Microbial detection techniques to find sea animals.
• Studying the mechanisms in deep-sea hydrothermal vent bacteria.
• Production of antibiotics using marine fungi.
• Exploring the biotechnological potential of Jellyfish associated microbiome.  
• Exploring the potential of marine fungi in degrading plastics and polymers.
• Expl oring the biotechnological potential of dinoflagellates.

Green Biotechnology Research Paper Topics:

• Detection of endosulfan residues using biotechnology in agricultural products.
• Development of ELISA technique for the detection of crops’ viruses.
• Use of Green Fluorescent Protein (GFP) as a cytoplasmic folding reporter.
• E.coli as an all-rounder in biotechnological studies.
• Improving the water quality for drinking using E.coli consortium.
• E.coli characterization isolated from the zoo animals’ feces.  
• Biocatalysis and agricultural biotechnology in situ studies.
• Improving the insect resistance of the crops.
• Improving the nutritional value and longer shelf life of GM crops.
• Improving the qualities of hydroponic GM plants.
• Reducing the cost of agriculture using bio-tools.
• Production of heavy cotton balls in agricultural biotechnology using in situ technique.
• Steps to minimize soil erosion using the tools of biotechnology.
• Enhancement of vitamin levels in GM Foods .
• Improving pesticide delivery using biotechnology.
• Comparison of folate biofortification of different crops.
• Photovoltaic-based production of crops in the ocean.
• Application of nanotechnology in the agricultural sector.
• Study the water stress tolerance mechanisms in model plants.

Combination and Analytical Topics:

• Sequencing of infectious microbes using molecular probes.
• Production and testing of human immune boosters in experimental organisms.
• Comparative genomic analysis using the tools of bioinformatics.
• Arabinogalactan protein sequencing using computational methods.
• Comparative analysis of different protein purification techniques.
• Oligonucleotide microarrays used in the diagnosis of the microbes.
• Uses of different techniques in biomedical research including microarray technology.
• Microbial consortium used to produce the greenhouse effect.
• Computational analysis of different proteins obtained from marine microbiota.
• Gene mapping of E.coli using different microbial tools.
• Computational analysis and characterization of the crystallized proteins in nature.
• Improving the strains of cyanobacterium using gene sequencing.
• mTERF protein used to terminate the mitochondrial DNA transcription in algae.  
• Reverse phase column chromatography used to separate proteins.
• Study of different proteins present in Mycobacterium leprae.
• Study the strategies best suitable for cloning RNA
• Study the application of nanocarriers for the gene expression in model plants.
• Exploring thermotolerant microorganisms for their biotechnological potential.

Biotechnology is full of research prospects. Various research and development companies are working day and night to achieve the required outcomes for different branches of biotechnology. If you find these list of Biotechnology research topics helpful, you may visit our blog for further assistance.

Also look for Biology Research Topics

Related Posts

Top safety measures for small vehicle owners on..., balancing free speech and user safety in the..., the ultimate guide to e-commerce website design, unable to work after an injury, securing fair treatment after workplace injuries, anton kreil – trading masterclass course: an over-review, the legal path: navigating road accident claims with..., these are the best chess openings for black, how to edit an essay well, busted for dui your comprehensive guide to legal....

I find this helpful.

I found this very helpful

I found it helpful

Leave a Comment Cancel Reply

Please enter an answer in digits:

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• Correspondence
• Published: 22 April 2024

Why Japan lacks a vibrant biotech industry

• Mark Kessel 1 &
• Chris Vickrey 2  

Nature Biotechnology ( 2024 ) Cite this article

Metrics details

• Biological techniques
• Business and industry

Recent analysis of the biopharmaceutical industry in Japan has emphasized that the lack of a thriving biotech ecosystem in that country is largely due to tight controls on drug pricing 1 . However, this is only one part of the explanation, and any strategy to promote Japanese biotech must acknowledge the full complexity of the problem. Japan has long punched above its weight in innovative research in biochemistry and medicinal chemistry despite relative government underinvestment compared with the United States and Europe. In the United States, 363 new drugs were approved by the Food and Drug Administration between 2011 and 2021 (ref. 2 ). The leading country of origin of these approvals was the United States, with 223 drugs, but Japan was the second-leading country of origin, with 33 drugs. Drugs first developed in Japan include statins (Sankyo) and the cancer immunotherapy Opdivo (nivolumab; Ono Pharmaceutical), based on the discovery of programmed death inhibitor proteins by Nobel prize recipient Tasuku Honjo. In the field of biotechnology, Japanese successes include BioWa (acquired by Kirin), a producer of monoclonal antibodies, and Chugai Pharmaceutical, which has the largest bioreactor capacity in Japan and has been fed a steady stream of new drugs from its majority owner Roche.

Yet Japan lacks a home-grown biotech ecosystem. Even the discovery of induced pluripotent stem cells by Kyoto University researcher Shinya Yamanaka has not translated into Japanese leadership in cell therapies. Several factors beyond drug price controls are involved. Although many Japanese pharmaceutical companies have corporate venture capital arms and invest in biotech startups, these investments are mostly in the United States and other regions outside Japan. The same is true of Japanese venture capital investing as a whole. In 2022, this sector invested 120 times more in the United States than in Japan 3 , 4 . Japan has simply failed to develop a startup ecosystem, especially in biotech. According to the Global Startup Ecosystem Report 2021 from Startup Genome, Tokyo ranked ninth in the world as a startup hub, below other cities in East Asia, including Beijing and Shanghai 4 .

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

195,33 € per year

only 16,28 € per issue

Buy this article

• Purchase on Springer Link
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Ezell, S. How Japan squandered its biopharmaceutical competitiveness: a cautionary tale. https://itif.org/publications/2022/07/25/how-japan-squandered-its-biopharmaceutical-competitiveness-a-cautionary-tale/ (Information Technology and Innovation Foundation, 2022).

National Venture Capital Association. Yearbook 2023. https://nvca.org/wp-content/uploads/2023/03/NVCA-2023-Yearbook_FINALFINAL.pdf (2023)

Venture Enterprise Center. VEC yearbook 2023. https://www.vec.or.jp/en (2023).

Startup Genome. The global startup ecosystem report, GSER 2021. https://startupgenome.com/report/gser2021 (2021).

Download references

Author information

Authors and affiliations.

New York, NY, USA

Mark Kessel

Brooklyn, NY, USA

Chris Vickrey

You can also search for this author in PubMed   Google Scholar

Corresponding author

Correspondence to Mark Kessel .

Ethics declarations

Competing interests.

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article.

Kessel, M., Vickrey, C. Why Japan lacks a vibrant biotech industry. Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02227-x

Download citation

Published : 22 April 2024

DOI : https://doi.org/10.1038/s41587-024-02227-x

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Recent Trends in Food Biotechnology

Original Research 13 July 2023 Isolation and identification of protease-producing Bacillus amyloliquefaciens LX-6 and its application in the solid fermentation of soybean meal Xinyi Huang ,  4 more  and  Xiaoping Yu 1,375 views 0 citations

Review 28 June 2023 Pullulanase: unleashing the power of enzyme with a promising future in the food industry Bindu Naik ,  8 more  and  Sarvesh Rustagi 3,105 views 4 citations

Original Research 04 April 2023 Protein engineering of NADH pyrophosphatase for efficient biocatalytic production of reduced nicotinamide mononucleotide Ye Liu ,  7 more  and  Zheng-Hong Xu 1,838 views 1 citations

Loading... Review 24 October 2022 Bacteriocin: A natural approach for food safety and food security Dibyajit Lahiri ,  9 more  and  Rina Rani Ray 4,916 views 18 citations

AI tool creates 'synthetic' images of cells for enhanced microscopy analysis

Observing individual cells through microscopes can reveal a range of important cell biological phenomena that frequently play a role in human diseases, but the process of distinguishing single cells from each other and their background is extremely time consuming -- and a task that is well-suited for AI assistance.

AI models learn how to carry out such tasks by using a set of data that are annotated by humans, but the process of distinguishing cells from their background, called "single-cell segmentation," is both time-consuming and laborious. As a result, there are limited amount of annotated data to use in AI training sets. UC Santa Cruz researchers have developed a method to solve this by building a microscopy image generation AI model to create realistic images of single cells, which are then used as "synthetic data" to train an AI model to better carry out single cell-segmentation.

The new software is described in a new paper published in the journal iScience . The project was led by Assistant Professor of Biomolecular Engineering Ali Shariati and his graduate student Abolfazl Zargari. The model, called cGAN-Seg, is freely available on GitHub.

"The images that come out of our model are ready to be used to train segmentation models," Shariati said. "In a sense we are doing microscopy without a microscope, in that we are able to generate images that are very close to real images of cells in terms of the morphological details of the single cell. The beauty of it is that when they come out of the model, they are already annotated and labeled. The images show a ton of similarities to real images, which then allows us to generate new scenarios that have not been seen by our model during the training."

Images of individual cells seen through a microscope can help scientists learn about cell behavior and dynamics over time, improve disease detection, and find new medicines. Subcellular details such as texture can help researchers answer important questions, like if a cell is cancerous or not.

Manually finding and labeling the boundaries of cells from their background is extremely difficult, however, especially in tissue samples where there are many cells in an image. It could take researchers several days to manually perform cell segmentation on just 100 microscopy images.

Deep learning can speed up this process, but an initial data set of annotated images is needed to train the models -- at least thousands of images are needed as a baseline to train an accurate deep learning model. Even if the researchers can find and annotate 1,000 images, those images may not contain the variation of features that appear across different experimental conditions.

"You want to show your deep learning model works across different samples with different cell types and different image qualities," Zargari said. "For example if you train your model with high quality images, it's not going to be able to segment the low quality cell images. We can rarely find such a good data set in the microscopy field."

To address this issue, the researchers created an image-to-image generative AI model that takes a limited set of annotated, labeled cell images and generates more, introducing more intricate and varied subcellular features and structures to create a diverse set of "synthetic" images. Notably, they can generate annotated images with a high density of cells, which are especially difficult to annotate by hand and are especially relevant for studying tissues. This technique works to process and generate images of different cell types as well as different imaging modalities, such as those taken using fluorescence or histological staining.

Zargari, who led the development of the generative model, employed a commonly used AI algorithm called a "cycle generative adversarial network" for creating realistic images. The generative model is enhanced with so-called "augmentation functions" and a "style injecting network," which helps the generator to create a wide variety of high quality synthetic images that show different possibilities for what the cells could look like. To the researchers' knowledge, this is the first time style injecting techniques have been used in this context.

Then, this diverse set of synthetic images created by the generator are used to train a model to accurately carry out cell segmentation on new, real images taken during experiments.

"Using a limited data set, we can train a good generative model. Using that generative model, we are able to generate a more diverse and larger set of annotated, synthetic images. Using the generated synthetic images we can train a good segmentation model -- that is the main idea," Zagari said.

The researchers compared the results of their model using synthetic training data to more traditional methods of training AI to carry out cell segmentation across different types of cells. They found that their model produces significantly improved segmentation compared to models trained with conventional, limited training data. This confirms to the researchers that providing a more diverse dataset during training of the segmentation model improves performance.

Through these enhanced segmentation capabilities, the researchers will be able to better detect cells and study variability between individual cells, especially among stem cells. In the future, the researchers hope to use the technology they have developed to move beyond still images to generate videos, which can help them pinpoint which factors influence the fate of a cell early in its life and predict their future.

"We are generating synthetic images that can also be turned into a time lapse movie, where we can generate the unseen future of cells," Shariati said. "With that, we want to see if we are able to predict the future states of a cell, like if the cell is going to grow, migrate, differentiate or divide."

• Developmental Biology
• Biotechnology and Bioengineering
• Behavioral Science
• Biochemistry
• Electricity
• Computer Modeling
• Photography
• Mathematical Modeling
• 3D computer graphics
• Cell (biology)
• Adult stem cell
• Mammalian embryogenesis
• Resonance (chemistry)
• Model rocket

Story Source:

Materials provided by University of California - Santa Cruz . Original written by Emily Cerf. Note: Content may be edited for style and length.

Journal Reference :

• Abolfazl Zargari, Benjamin R. Topacio, Najmeh Mashhadi, S. Ali Shariati. Enhanced Cell Segmentation with Limited Training Datasets using Cycle Generative Adversarial Networks . iScience , 2024; 109740 DOI: 10.1016/j.isci.2024.109740

Cite This Page :

Explore More

• This Alloy Is Kinky
• Giant Galactic Explosion: Galaxy Pollution
• Flare Erupting Around a Black Hole
• Two Species Interbreeding Created New Butterfly
• Warming Antarctic Deep-Sea and Sea Level Rise
• Octopus Inspires New Suction Mechanism for ...
• Cities Sinking: Urban Populations at Risk
• Puzzle Solved About Ancient Galaxy
• How 3D Printers Can Give Robots a Soft Touch
• Combo of Multiple Health Stressors Harming Bees

Trending Topics

Strange & offbeat.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Biotechnol Healthc
• v.1(6); 2004 Dec

The 5 Most Pressing Ethical Issues in Biotech Medicine

Third-party payers, employers, providers, and policy makers face moral dilemmas relative to issues about clinical research, costs, and privacy.

Biotech healthcare is going through what every other emerging scientific discipline experiences – the challenge of defining its ethical boundaries. Research, costs, and privacy issues spawn concerns that third-party payers, employers, providers, and policy makers will face for years to come.

Ethical design of clinical trials was, by far, the most frequently cited ethical issue by our editorial board. Eric Wickstrom, PhD, says it is important to structure trials appropriately to obtain clear tests of hypotheses while protecting human subjects.

PHOTOGRAPH BY DON TRACY

In an age when medical technology improves with increasing rapidity, the availability of new treatments increases almost as quickly. With advances, however, come dilemmas — scientific, financial, and especially moral. These conundrums are likely to multiply as groups with vastly different viewpoints and resources battle over the direction of health policy.

As the first decade of the 21st century reaches its midpoint, B iotechnology H ealthcare has identified five topics that dominate ethical discussions of biotech medicine. 1 These issues will continue to generate controversy in the foreseeable future, forcing third-party payers, employer and union purchasers, and health care providers to deal with the policy implications of some or all of them for years.

1. Protecting Human Subjects in Clinical Trials

This issue has generated considerable debate since 1999, when 18-year-old Jesse Gelsinger died while participating in a gene therapy trial at the University of Pennsylvania. The institution was widely criticized for failing to disclose crucial information on informed consent documents, relaxing criteria for accepting volunteers, and enrolling volunteers who were ineligible. The episode prompted a great deal of soul-searching among researchers and regulators, and many universities began implementing new standards as a result of the harsh spotlight that was cast on the clinical trial world.

In a 2002 article in Epidemiology Review , Jeremy Sugarman, MD, MPH, a professor of bioethics and medicine at the Johns Hopkins School of Medicine, wrote, “It is critical to ensure that research is conducted responsibly throughout the entire study cycle, from the way participants are selected to the way data are entered, analyzed, and reported. Attention to each aspect of research conduct is necessary to the success of the scientific enterprise and to the protection of study participants and others from unnecessary harm.”

Conundrum: At what point does cost sharing backfire? A 20 percent coinsurance on a $20,000 therapy may work actuarially but could foster patient nonadherence.

The issue, of course, is complicated, because patients — especially suffering patients — are willing to try something new, even when physicians acknowledge that a complete side-effect profile isn’t known, according to Eric Wickstrom, PhD, a professor of biochemistry and molecular pharmacology at Jefferson Medical College. This headlong rush by ailing volunteers, he says, necessitates rigorous protection by review committees, even before patients see an informed consent form. This is especially true, he says, for some vaccines and gene therapy.

“Gene therapy hasn’t really worked yet, and it necessitates a great deal of care,” explains Wickstrom.

The Gelsinger episode, though, raised another sticking point — financial conflicts of interest. In this case, the lead researcher, James Wilson, MD, failed to disclose in the consent form that he had founded a company that stood to profit from the research.

Arthur L. Caplan, PhD, 2 who heads the Center for Bioethics at the University of Pennsylvania, stressed in a recent interview with B iotechnology H ealthcare that researchers must ensure that clinical trials are not distorted by incongruous arrangements. In addition, he says, volunteers should not be recruited in a manner that would suggest that they are being paid bribes, as opposed to reimbursement for legitimate expenses.

2. Affordability

The rising cost of healthcare — and the cost of medications in particular — is a political hot potato and will remain so. No matter what the U.S. Food and Drug Administration might say or attempt, a large swath of the public, their federal representatives, and their governors do not seem to believe the pharmaceutical industry’s argument that research and development are funded by today’s prices and that price controls could retard R&D.

The ethical concerns are likely to get still more heated when the value of expensive biotech treatments for chronic illnesses is debated. After all, a needed pill for cholesterol might cost $3 daily, which amounts to nearly $1,100 per year. Compare that to a biologic that carries a $20,000-per-year price tag — or something even more costly.

The cost of defending the United States against bioterrorism raises a host of issues, says David Krause, MD, of Vicuron Pharmaceuticals. “If we fund this, what are we not funding?” he asks. “And can we ever predict all the possible terror threats?”

“Affordability is, arguably, an issue across the board,” says Jeff Kimmell, RPh, vice president of healthcare services and chief pharmacy officer at drugstore.com , in Bellevue, Wash. “In the United States, we say we want the best [treatments]. But it’s also an ethical dilemma. At what point will people say ‘Enough is enough?’”

This may place payers and purchasers, who are already struggling with the question of how much cost sharing is appropriate, on the defensive. Insurers and employers juggle actuarial concerns with the risks of patient nonadherence and its potential for poor clinical outcomes when coverage decisions are made. The ethical questions do not fit neatly into this decision-making process but, rather, transcend it.

What happens when some patients can’t afford the out-of-pocket share of a given treatment? What if an insurer declines to add a biologic to its formulary because of its acquisition cost? What happens when a patient on an expensive chronic therapy maxes out his lifetime insurance benefit? Such instances may not be the norm, but their possibility disturbs some experts who see a pivotal clash between patients and profits.

“It’s certainly an economic issue if biologics are priced so high that some patients are priced out of the market,” says Sean Nicholson, PhD, assistant professor of policy analysis and management at Cornell University. “Perhaps an insurer may not cover a particular therapy. If there’s nothing else the patient could take to save his or her life, or to improve quality of life, that’s a dilemma.”

Talk about a Pandora’s box. Protecting patient privacy is a growing concern, thanks to technology that is making it possible to decode the human genome. But as scientists become adept at deciphering a person’s genetic composition, it is increasingly likely that compromising information about a person’s future health is going to become available.

This creates enormous problems. For instance, it may become possible to know that a 5-year-old is going to develop serious heart disease later in life, but does a prospective employer have the right to know that? How will this knowledge affect the individual’s ability to obtain a job, insurance, or a mortgage? Should such information be available to insurers and others? This is a thorny problem destined to become only thornier.

“Take a genetic test that comes back positive, and the biologic treatment of the patient costs $1 million,” says F. Randy Vogenberg, RPh, PhD, senior vice president and national practice council leader at Aon Consulting, in Providence, R.I. “What does an insurer do with that knowledge? It can’t tell the employer, but it does have a fiduciary responsibility as the health plan to remain within stated benefit coverage premiums and costs.

“It’s going to be very tricky for health plans to deal with this. And it won’t just be on a case-by-case basis, but it will come up during plan renewals and bidding.”

Sound far-fetched? Not really, says Vogenberg. “Generally speaking, everybody so far has stuck their heads in the sand. HIPAA offers some protection, but as diagnostics expand, this issue will bubble to the surface. And probably, litigation will determine some boundaries.”

To nip the problem in the bud, some attempts are being made to put rules in place now. An American College of Physicians working group published one such effort in the Annals of Internal Medicine in July; an article titled “Ethics in Practice: Managed Care and the Changing Health Care Environment” spelled out a statement of ethical principles for health plans, purchasers, and physicians. One section opined that “All parties have an ethical obligation to protect the confidentiality of patient health care information. In general, identifiable patient information should not be shared without the patient’s consent — except where the health and safety of individual persons or the public may be threatened, or as required by law.”

Conundrum: What does an insurer do with the knowledge that a person is predisposed to a condition that costs $1 million to treat? It can’t tell the employer, but it has a fiduciary responsibility to remain within stated benefit coverage premiums and costs.

Even this statement, however, leaves open the question about the extent to which an individual’s rights may be eclipsed by societal needs. This is especially true in the wake of the Patriot Act. In reflecting public fears about terrorism, the federal law is causing a raging debate over an individual’s right to privacy and the safety concerns of a society at large. With legal challenges pending, it is easy to see how even the ethics statement for managed care may cause difficulties.

4. Stem Cell Research

This one shouldn’t be a surprise. Stem cell research is anathema to the religious right and worked its way into the recent presidential election.

To circumvent the funding roadblocks in Washington, D.C., some states — such as New Jersey and California — are looking past ethical objections and taking serious steps to foster establishment of stem cell research centers. In California, birthplace of the biotech revolution and a state hard hit by the dot-com collapse, voters sized up the potential economic value of stem cell research and overwhelmingly passed Proposition 71, which guarantees $3 billion in state funding over the next decade.

It is somewhat ironic that a scientific area of research based on trials and data could be reconfigured into an emotional issue. The debate, of course, pits people who believe the research may one day find cures for diseases against others who say it violates human life.

On one side, the American Society of Clinical Oncology issued this policy statement in 1999: “Whether privately or publicly funded, researchers should be mindful of the ethical issues that may be raised when research involves embryos, fetal tissue, cloning, or other controversial questions. Nevertheless, medical research often requires a balancing of perceived risks against potential benefits. The tremendous potential of stem cell research for the treatment of diseases ... means that the balance of benefits and risks is now clearly in favor of going forward with the research, even if it involves ethically sensitive areas.”

On the other hand, the founding statement of Do No Harm – The Coalition of Americans for Research Ethics argues: “Stem cell research promises great good and is a worthy scientific priority as long as we pursue it ethically. Obtaining stem cells from people without seriously harming people in the process can be ethical. However, obtaining stem cells from human embryos cannot be ethical because it necessarily involves destroying those embryos.”

For now, say experts, the debate is largely hypothetical for insurers.

“Although it is still early in the process, it is likely that the managed care industry will continue to monitor this ethically sensitive area, particularly as the potential benefits and costs begin to outweigh the risks,” says Mitchell P. DeKoven, manager of reimbursement services at PharmAnalysis Group, MED-TAP’s Center for Pricing & Reimbursement, in Arlington, Va.

5. Defending the United States Against Bioterrorism

Security is hugely important, and public fears over terrorism are unlikely to diminish. In response, the federal government wants Project Bioshield to spur the development of treatments, including preventive medications and vaccines, that would be available in sufficient quantities to protect the largest possible number of people.

The congressional impetus is obvious, according to Chuck Ludlam, general counsel on the staff of Democratic Sen. Joseph Lieberman of Connecticut. In a recent speech, Ludlam said that economic losses caused by a successful bioterror attack in a densely populated area could be massive.

But Project Bioshield also raises ethical problems, experts say. For starters, the investment will be large and probably will grow over time. At a time when deficits are growing, generous funding for bioterrorism research suggests that funding for other public health priorities — such as diseases that are becoming more prevalent — may suffer.

“If we fund this, what are we not funding? And how do you divide the pie?” asks David Krause, MD, senior vice president of clinical research and medical affairs at Vicuron Pharmaceuticals, in King of Prussia, Pa. “And that’s just part of the problem. We don’t know if anybody will ever die from bioterrorism. We don’t know what the threat is. Can we ever predict all the possible terror threats and provide protection against them?”

Krause isn’t alone in observing that there is an unpredictable number of portals for bioterrorists to wreak havoc on the United States. The Infectious Diseases Society of America wants the scope of Project Bioshield extended to include all areas of infectious disease research and development, especially for antibiotics to treat existing drug-resistant infections.

“There is an inextricably linked, synergistic relationship between research and development efforts needed to protect against both naturally occurring infections and bioterrorism agents,” said John Bartlett, chief of the division of infectious diseases at the Johns Hopkins School of Medicine and chair of an IDSA task force, in testimony given recently before the U.S. Senate Committee on Health, Education, Labor and Pensions, and the Senate Judiciary Committee.

On the positive side, bioterrorism research may yield the same sort of consumer-product payoff NASA research did — in this case, Ludlam noted, possibly indirectly helping to find medicines to treat infections with HIV and viruses that cause hepatitis, Lyme disease, polio, West Nile, and the common cold. The effort also could lead to medicines for bacteria, such as those causing tuberculosis, pneumonia, salmonellosis, malaria, sepsis, or sexually transmitted diseases.

A subsidiary ethical issue to bioterrorism research, says Krause, is clinical testing. Human subjects couldn’t be used in smallpox trials, for instance, so surrogate markers are required. This can make it difficult to determine the effectiveness of an antiterrorism agent.

“We’re talking about an expensive insurance policy and, like any insurance policy, you hope you never have to use it,” says Krause. “You want it in your plan, but at the same time, it’s not a slam dunk.”

1 About our methodology: The editors selected and ranked the five broad topics in this article on the basis of the results of a questionnaire distributed to the B iotechnology H ealthcare editorial board. The editorial board (see page 3) represents numerous disciplines, and includes physicians, pharmacists, researchers, ethicists, insurers, managed care executives, employers, government policy experts, and consultants.

2 Astute readers will recall that Caplan had a courtesy appointment to Wilson’s department and provided him with informal advice about enrolling patients in gene therapy trials. Caplan, who has been active in his career in pushing informed-consent reforms, ultimately was found to have no responsibility in the Gelsinger case.

• A*STAR Board Members
• Senior Management
• Organisation Structure
• Corporate Social Responsibility
• Diversity at A*STAR
• Annual Reports
• A*STAR Graduate Academy (A*GA)
• Innovation and Enterprise (I&E)
• Research Entities
• About A*STAR Research
• Directory of Researchers
• Funding Opportunities
• Research Focus
• Research Quality Excellence
• Biomedical Research Council
• Science and Engineering Research Council
• A*STAR Horizontal Technology Coordinating Offices (HTCO)
• Research Entities Capabilities
• Honours and Accolades
• Highly Cited Researchers
• About I&E
• Innovation Offerings
• Innovation Platforms
• Work with I&E
• About A*STAR Scholarships
• A*STAR Research Internship Award (ARIA)
• National Science Scholarship (BS-PhD)
• Singapore International Pre-Graduate Award (SIPGA)
• National Science Scholarship (Masters)
• National Science Scholarship (PhD)
• A*STAR Computing & Information Science Scholarship
• A*STAR Graduate Scholarship
• Singapore International Graduate Award (SINGA)
• A*STAR Research Attachment Programme (ARAP)
• A*STAR International Fellowship
• A*STAR Science Award (Upper Sec)
• A*STAR Science Award (JC)
• A*STAR Science Award (Poly)
• H3 Research Attachment Programme
• A*STAR - MOE Attachment
• Research Attachments at A*STAR RIs
• A*STAR Scholars
• Featured Scholars
• International Awardees
• Developmental Opportunities for A*STAR Scholars
• Scholarship Award Ceremony 2023
• FAQs For Scholarships and Awards
• A*STAR News
• A*STAR Innovate
• Faces of A*STAR
• National Survey of RIE
• Connect with Us

A*STAR NEWS

• Publicity Highlights
• Press Releases
• COVID-19 R&D

How Singapore Punches Above Its Weight In Advancing Drug Discovery And Development

By Dr Hao Weidong, Chief Scientific Officer, Experimental Drug Development Centre

• The Singapore government's long-term commitment to building the biomedical science ecosystem is not only yielding results for the economy, but enabling strategic business partnerships, talent attraction and innovative breakthroughs in drug discovery.

When I was presented with the opportunity to work in Singapore, I was very impressed by the high-impact publications by researchers from the various biomedical research institutes here. What ultimately pushed me to make the move to Singapore was the exciting opportunity to work across various biomedical research institutes in the ecosystem and the chance to participate in Singapore's concerted translational efforts to advance drug discovery and development. My brother, who had worked and lived in Singapore for several years, also strongly encouraged me to take up this offer.

Promising outlook for biotech in Singapore

Over the last three decades, the Singapore government has sustained investments in research, innovation, and enterprise (RIE), with the RIE2025 plan dedicating about S$25 billion to research and development (R&D). An additional S$3 billion will be injected this year to deepen capabilities in new growth areas 1 .

Singapore's R&D efforts have yielded positive societal outcomes and economic growth. In 2021, there were more than 25,000 people working in the field, many of whom had high-paying and high-value jobs. This strong collaboration among ecosystem players in striving towards a common goal was one of the key reasons that attracted me to Singapore.

Based on a report by global strategy firm LEK Consulting, the number of Singapore-based biotechnology companies grew substantially from 7 in 2012 to 52 in 2022, with this number projected to increase by over 61.5 percent between 2022 and 2032. Looking at the venture funding landscape, DealStreetAsia and Enterprise Singapore reported that start-ups in the healthcare sector closed 67 deals with a cumulative value of US$0.97 billion in the past two years, despite the recent global downturn in biotech investments.

Advancements have fluctuated during the past two decades; various regions around the world have attempted to create biotech hubs with varying levels of success. But towards the end of 2023, Singapore saw an increase in investor interest and new biotech incubators launched. For instance, in November, Flagship Pioneering announced the opening of a regional hub in Singapore for expansion in the Asia-Pacific region.

While Singapore's biotech achievements may seem small in comparison to other regions in the world, I believe Singapore is in a good position to punch above its weight. What sets Singapore apart is its geographical location in the heart of Asia, its long-term commitment to invest in R&D and talent, and its strong belief in meaningful partnerships and synergistic collaborations.

Drawing on collective strengths

Singapore overcomes the constraints of its size by combining efforts and working with partners to draw on collective strengths. It is no different in the biotech space: research institutes, universities, hospitals, MNCs, startups and government agencies like the Agency for Science, Technology and Research (A*STAR) work in unison towards a common goal.

To foster the growth of biotech and deep-tech start-ups in general, several incubator spaces have been set up in Singapore. For example, A*StartCentral (A*SC) was championed by A*STAR to provide space, mentorship, and funding to support A*STAR spin-offs and external start-ups. A*SC has supported around 140 start-ups, half of which are biotechs. Between 2016 and 2022, the startups incubated there had raised more than S$950 million in funding. In my opinion, these are significant figures given Singapore's size.

Grow your startup with A*StartCentral!

Several incubators have also emerged from synergistic collaborations in recent years. A tripartite alliance between Nanyang Technological University (NTU), A*STAR, and the National Healthcare Group gave birth to co11ab , a biomedtech incubator embedded in the Lee Kong Chian School of Medicine at NTU, situated near healthcare institutions such as hospitals.

Furthermore, Singapore has drawn the attention of international collaborators. In September last year, Johnson & Johnson partnered the Singapore Economic Development Board to set up JLABS, which helps early-stage biotechs in Singapore translate their research into solutions. A month after, global life science company Evotec SE partnered both local and global venture capitals to launch 65LAB , which supports biotechs in achieving commercial success and creating positive patient impact.

I experience this spirit of collaboration keenly in my role as the Chief Scientific Officer of the Experimental Drug Development Centre (EDDC) . EDDC is a national platform for drug discovery and development. We work closely with many partners to translate publicly funded local research into commercialised drugs.

This includes out-licensing drug candidates developed with our partners in Singapore's ecosystem to foreign biotechs and big pharma. Our pipeline includes small molecules and biologics that span various diseases, including oncology, fibrosis, infectious diseases, ophthalmology, and autoimmune diseases like lupus. To this end, I highlight some key success stories.

We have out-licensed a panel of cancer-specific antibodies—a product of the close multi-institutional collaboration between A*STAR, EDDC, and the Singapore Gastric Cancer Consortium—to Boehringer Ingelheim. Under the global licensing agreement, Boehringer Ingelheim will advance the preclinical and clinical development as well as the commercialisation of these antibodies. We have also collaborated with NTU on compounds against multidrug-resistant tuberculosis, which were licensed to US-based Neuro-Horizon Pharma for commercialisation.

Licensing Agreement With Boehringer Ingelheim To Develop Targeted Cancer Therapies

EDDC has also played an instrumental role in helping local biotechs grow. In 2018, we out-licensed the cancer drug ETC-206, developed at EDDC, to Singapore biotech AUM Biosciences. The company went on to raise US$27 million to fund their research and has partnered big pharma MSD and Roche to run clinical trials.

EDDC itself sponsors and oversees clinical trials that it initiates. Singapore achieved a major milestone in 2023 with EBC-129, the first made-in-Singapore antibody-drug conjugate (ADC) that was made possible by the collaborative efforts of EDDC, A*STAR research institutes, and the National Cancer Centre Singapore. EBC-129 has been approved by the US Food and Drug Administration to enter first-in-human clinical trials for solid tumours.

First Made-In-Singapore Antibody Drug Conjugate Enters Clinical Trials

Well-positioned for Asian-centered research

Situated at the heart of Southeast Asia, Singapore's central location fosters a melting pot of diverse ethnicities, making it an ideal hub for collecting and researching data on the varied DNA and genomes that constitute the Asian phenotype. The racial diversity of Singapore's population—which mainly comprises Chinese, Malays, and Indians—allows us to capture Asia's genetic diversity effectively.

Singapore has invested significantly in large-scale and longitudinal studies to develop well-characterised and deeply phenotyped datasets. In the era of precision medicine, these datasets provide valuable information on the Asian population and fill in the knowledge gaps of existing datasets that are often Euro-centric. This is important as Asian populations often have differing disease phenotypes from Western populations for conditions such as cardiovascular (CV) disease and cancer. Our datasets can thus be leveraged to discover biomarkers for better diagnostics and patient stratification, as well as drug targets for more precise therapeutic interventions.

One of Singapore's most ambitious initiatives in this space is Precision Health Research Singapore (PRECISE) – a central entity implementing Singapore's National Precision Medicine Strategy across government, research and health clusters and private industries. The genomes of 100,000 Singaporeans are being sequenced with the goal of creating an Asian reference genome that addresses the underrepresentation of Southeast Asian populations in existing genomic datasets. PRECISE has also put in place robust data governance measures to ensure data privacy and protection.

Singapore has also created the Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT), which uses genetic, clinical, and imaging data from an existing study on heart failure that spans 11 countries in Asia. The ATTRaCT platform integrates top expertise in cardiovascular clinical and biomedical sciences across the nation, bringing together A*STAR research institutes, with Singapore's national heart institutions as well as academic institutions.

The Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT)

The robust dataset includes longitudinal follow-ups on patient outcomes as well as community-based controls. ATTRaCT will provide valuable insights to guide R&D on cardiovascular disease progression, enabling the discovery of new drug targets and drug repurposing to improve clinical strategies for Asian patients with heart failure.

Commitment to build up R&D and nurture talent

As the saying goes: 积土成山，风雨兴焉；积水成渊，蛟龙生焉. For any industry at its nascent stage, significant funding is needed to nurture growth so that the industry can become self-sustaining. I believe the Singapore government has done well in this regard by providing substantial public funding to build up R&D and nurture talent.

In terms of infrastructure, Singapore has created Biopolis and Fusionopolis — R&D hubs that bring together biomedical and science & engineering capabilities to seed new areas of research and business. Housing EDDC, and many of A*STAR's research institutes, the precinct is a fertile ground for inter-disciplinary collaborations to foster innovation, and support public and private organisations embarking on end-to-end business activities.

Singapore also prioritises talent development. A*STAR offers academic scholarships to train scientific talent who will eventually contribute to Singapore. Other efforts include the Singapore Biodesign (SB) Innovation Fellowship Programme (IFP) . The SB fellowship focuses on entrepreneurial talent in the health technology sector, while the IFP targets mid-career professionals who wish to develop technology commercialisation skills. Overall, these talent development efforts help provide skilled labour for Singapore's R&D ecosystem.

Nurturing Talent with A*STAR Graduate Academy

A promising trajectory

Looking forward, I have a bullish outlook on Singapore's biomedical sector. The government has long-term committed investments in the sector. Moreover, the nation's conducive business environment and favourable government policies are attracting biopharma companies and venture firms, including Chinese companies and firms, which are considering Singapore for its strategic position in Asia. More and more businesses setting up shop in Singapore bodes well for the sector's growth and future.

In addition to seeing Singapore become a regional biomedical hub, I hope to witness the successful commercial launch of more made-in-Singapore biopharmaceutical products by Singapore-based entities in the coming years. With more of such accomplishments, we can then truly say that we have ushered in Singapore's biotech era.

For this to happen, I believe local stakeholders should continue to work collaboratively to build up our drug discovery and development capabilities within the ecosystem, leverage technologies such as automation and AI, and forge strategic partnerships with global multinational corporations, to further Singapore's translation of innovative research to novel drug candidates and viable therapeutics.

Our Success Stories

Collaborate with A*STAR

1 DPM Heng Swee Keat at the Debate on the Budget Statement

Was This Article Helpful ?

A*STAR celebrates International Women's Day

From groundbreaking discoveries to cutting-edge research, our researchers are empowering the next generation of female science, technology, engineering and mathematics (STEM) leaders. Get inspired by our #WomeninSTEM

The biotech investment landscape in 2024

RTW Investments is a global multi-strategy investment firm focused on supporting innovative biotech and biopharma companies across the US, Europe, and China. To get an overview of what’s happening in financing for biotech companies in 2024, we had a conversation with Stephanie Sirota, chief business officer of RTW Investments.

Table of contents

About rtw investments.

The company invests in both public and private companies across their entire life cycle, with a focus on those addressing next-generation gene and RNA therapies , rare diseases, targeted oncological, cardiovascular, and neurological disorders, and more.

RTW Investments is a $7 billion full life cycle investment firm focused on the most innovative sectors across biotechnology and medtech. 

The company has been in existence since 2009, and has a global presence in the space, with offices in New York, London and Shanghai. 

“About eight, nine years ago, together with a few other specialist investors, we started investing in late-stage privates and pre IPO rounds, and we built that crossover ecosystem. And the irony is that we were able to do it with not that much capital,” Sirota explained. 

“As companies and management teams got smarter around who should be supporting their company as they move into the public arena, it became clear that the specialist investor who had a public business could continue to support those companies. So that was kind of how the crossover ecosystem and biotech evolved. And we were one of the leaders in that.”

The first company RTW Investments created was gene therapy company Rocket Pharmaceuticals.

“We started that in our back conference room with the idea that there were a lot of very interesting assets that were moving through academic hands that were ready to go into human clinical trials and needed more capital and someone drive those programs forward out of academia,” Sirota said.

How do funding firms assess biotech investments in 2024?

The importance of a science-driven approach.

Sirota said when evaluating any company, the science comes first. Then, this is coupled with what she said is a “Warren Buffett like framework” for evaluating the valuation of a company. The competitive landscape is also taken into consideration.

“I would say that our favorite investment is where we identify an asset that we believe is going to have a meaningful transformational effect, not just a short-term momentum-driven step up, but we’re looking for things where we can get multiples of return because we’re identifying value before the rest of the market has identified that.”

During Sirota’s 12 years at RTW Investments, she has seen the company triple the number of modalities that can address diseases. 

“It’s not just small molecules and antibodies, but we have gene replacement therapy, we have gene editing, we have antibody drug conjugates, we have protein degraders. There are so many ways to address diseases. We definitely follow the advancements in modalities, but then we also look across disease areas and look across therapeutic areas. So these days we’re very excited about metabolic and obesity and some of the adjacencies like liver diseases,” she explained.

Data and disruption: cornerstones of biotech investment strategy in 2024

Sirota said it’s important for investors to keep up with the research in every area to recognize when there is a game-changing opportunity.

“Our process really starts with data collection. We even have a team that supports the research team. And together, we probably attend in person and also remotely over 200 medical conferences a year. And that is critically important to our process because we need to have that primary scientific data.”

“When you have a market downturn, the competition for capital is fierce.”

Sirota said that RTW Investments tends to stay away from crowded areas. 

“We really look for drugs that we think are going to be placing and disrupting that current standard of care or bringing a new standard of care about. Our level of involvement is going to be determined based on the need. If something is already in a public company, and that public company is fine and has a sophisticated management team, we will, for the most part, be just a passive investor. And that, I would say, is the majority of our investments.”

Trends for 2024 impacting the biotech investment landscape

Funding challenges.

A lot of biotech companies have struggled to find funding , and it remains a topic of conversation. Sirota said it was not just the down market that impacted the funding environment. 

“If you go back, the two years before that were exceptional and it was very easy for companies to go to IPO and to get a very rich step up to their last round. And we saw a lot of companies go public pretty early, even earlier than they normally do. So, you had preclinical companies in that public sphere. And, you know, when you have a market downturn, the competition for capital is fierce. 

“Generalist investors exit the space, and then you’re left with specialists like ourselves who have to really be intentional about which companies we want to fund . And unfortunately, in that sort of competition for capital, not everyone is going to be able to get to the same size check.”

However, Sirota believes the environment today is better, albeit without the capital from the generalist investors.

Mergers and acquisitions

Sirota said the trend toward more mergers and acquisitions was strong last year, and it is expected to continue.

“That’s the beauty of this symbiotic relationship between biotech and big pharma. Biotech can be nimble and can make really meaningful advancements. And at some point, the large companies, whether it’s big pharma or large biotech, they have the ability to sell a drug and to properly commercialize it and to take those approved therapies and bring them to global markets. A biotech company, particularly a small or even a mid-sized biotech company, doesn’t always have the capability of doing it on its own,” Sirota noted.

She explained that there have been around a dozen deals this year already with an average premium of more than 100%. The M&A activity has been across subsectors, and the trend is going to continue.

The IPO market

It seems as though the initial public offerings (IPO) market was a bit quieter in 2023, however Sirota said there have already been eight IPOs in 2024 compared to 11 in 2023.

“Of the IPOs this year, less than half of them are actually trading above their IPO price. We think that folks are probably going to be a little bit more selective about taking something public until they know if that’s a real chance of continuing to hit some of those milestones. So that’s going to be a determining factor,” Sirota said.

A wave of positive clinical data

Sirota said that so far, 2024 has been highlighted by strong clinical data. She expressed hope that this translates into more confidence from other funders and other sources of capital. 

Sirota also said the FDA has also become “a bit friendlier.”  

A part of this, she explained, was due to so many resources having gone into COVID, as well as burnout. She said a lot of drug reviewers left, with less experienced staff filling in, leading to a more conservative approach.

“Now, particularly with someone like Peter Marks, who’s a real champion of gene therapies and genetic medicines, we’re seeing some approvals and the FDA is friendlier. Hopefully, with a wave of positive clinical data from biotech companies, and then also a stable or hopefully a lower interest rate environment, all that capital is going to come crashing back.”

The royalties market: a growing area of funding for biotech investments in 2024

One growing area of funding is the royalties market. Sirota explained that there will be a competitive bid around a commercial product, with financiers competing for a slice of that royalty stream. 

“Generally, they’re looking for an existing commercial product that the revenues are known and you don’t have to spend a lot of time figuring out or predicting what that commercial is going to look like,” Sirota noted.

Sirota said when a company has a drug approved, it’s necessary predict how much revenue the drug will achieve, as well as peak sales.

“There will obviously be a Wall Street consensus around this. But we have a team, and we’ve been doing this for the last 15 years, working on commercial forecasting. We look at every drug that launches every year and try to assess what we think that commercial forecast is going to look like. Not a lot of people are doing this. And so we can approach a company and then offer them a deal to give them money in exchange for a percentage of those revenues,” Sirota stated.

“So, we’re buying, call it 5% of the revenue stream of a particular drug for its capital life. And this is non-dilutive, so in some way it has that difference from raising equity. It’s a lower cost of capital than equity, but then it’s not as burdensome to a company’s balance sheet like debt would be.”

« RETURN TO NEWS

Merck, A&T launch joint Merck Biotechnology Learning Center

04/19/2024 Research and Economic Development

• 4-H and Youth Development News
• Academic Affairs News
• Accounting and Finance News
• Administration and Instructional Services News
• Admissions News
• Agribusiness, Applied Economics and Agriscience Education News
• Agricultural and Natural Resources News
• Alumni News
• Animal Sciences News
• Applied Engineering Technology News
• Athletics News
• Biology News
• Built Environment News
• Business and Finance News
• Business Education News
• Chancellor's Speaker Series
• Chancellors Town Hall Series
• Chemical, Biological, and Bio Engineering News
• Chemistry News
• Civil, Architectural and Environmental Engineering News
• College News
• Community and Rural Development News
• Computational Science and Engineering News
• Computer Science News
• Computer Systems Technology News
• Cooperative Extension News
• Counseling News
• Criminal Justice News
• Deese College News
• Economics News
• Educator Preparation News
• Electrical and Computer Engineering News
• Employees News
• Energy and Environmental Systems News
• English Department News
• Family and Consumer Sciences News
• Graphic Design Technology News
• Hairston College News
• Headlines News
• History & Political Science News
• Honors College News
• Human Resources News
• Industrial and Systems Engineering News
• Information Technology Services News
• Innovation Station News
• Journalism & Mass Communication
• Kinesiology News
• Leadership Studies and Adult Education News
• Liberal Studies News
• Library News
• Magazine News
• Management News
• Marketing News
• Mathematics News
• Mechanical Engineering News
• Media Spotlight News
• Natural Resources and Environmental Design News
• News Categories
• Nursing News
• Psychology News
• Research and Economic Development News
• Social Work News
• Student Affairs News
• Students News
• The Graduate College News
• Transportation & Supply Chain
• University Advancement News
• Visual & Performing Arts News

Collaboration supports student enrichment and workforce development in North Carolina

EAST GREENSBORO, N.C. (April 19, 2024) – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and North Carolina Agricultural and Technical State University announced today the opening of the Merck Biotechnology Learning Center at Gateway Research Park in Greensboro, North Carolina.

The Merck Biotechnology Learning Center is a 4,025-square-foot facility that includes classroom space, a process laboratory and state-of-the-art biopharmaceutical manufacturing equipment. In the Learning Center, students and Merck trainees will experience hands-on learning and advanced discovery opportunities to enhance academic programming and training for biotechnology careers.

"We are embarking on a significant journey with the launch of the Merck Biotechnology Learning Center and our collaboration with N.C. A&T,” said Sanat Chattopadhyay, executive vice president and president, Merck Manufacturing Division. “The Learning Center is not just a building; it's an incubator for innovation, a path to discovery, and a beacon guiding the next generation of thinkers, problem-solvers and leaders who will drive our industry forward.”

The opening was marked with a joint celebration that included senior leaders from both Merck and A&T, current and former A&T students, and local government officials, including North Carolina Commerce Secretary Machelle Baker Sanders. Attendees participated in tours of the lab and classroom facilities to see firsthand the immersive learning opportunities.

Merck and A&T, America’s premier historically Black doctoral research university, developed this collaboration based on mutual values of innovation, community engagement and a commitment to diversity and inclusion. The joint effort between Merck and A&T supports the increasing need for biotech training and education in North Carolina and highlights the importance of business and historically Black college and university (HBCU) cooperation in growing diverse talent in the biotech sector.

“The Merck Biotechnology Learning Center will provide opportunities for N.C. A&T students to understand what a career in biotech looks like,” said Amanda Taylor, vice president and plant manager at the Merck Manufacturing Division site in Durham, North Carolina. “We have several wonderful N.C. A&T graduates working at our Durham site already, and there is so much growth in manufacturing across North Carolina. Through our collaboration with N.C. A&T, we’re developing new and innovative ways to build a pipeline of talent in the Triad and beyond.”

The opening of the Merck Biotechnology Learning Center is the launch of a long-term collaboration between Merck and A&T. The two organizations will partner on several initiatives to support student enrichment, including curricula development, a speaker series and STEM (Science, Technology, Engineering and Mathematics) community outreach.

“I am thrilled to announce our groundbreaking collaboration with Merck, which heralds a new era of innovation in biotechnology education," said Tonya Smith-Jackson, Ph.D., provost and executive vice chancellor of Academic Affairs. “This partnership signifies a union between academia and industry, and a commitment to excellence, innovation and the advancement of scientific knowledge, as it not only provides our students with unparalleled access to state-of-the-art labs, but also invaluable mentorship from Merck professionals, ensuring they emerge as industry-ready leaders poised to shape the future of biotechnology. The Merck Biotechnology Learning Center will serve as a hub of learning and discovery, and it is also the start of a collaboration where we are going to jointly advance the mission of both Merck and N.C. A&T.”

Merck has been a member of the North Carolina community for more than 40 years. Today, nearly 1,500 Merck colleagues work at North Carolina facilities in Durham and Wilson, including numerous A&T alumni. A&T's College of Engineering is the No. 1 producer of African American graduates in engineering in the United States.

Media Contact Information: [email protected]

Latest News

N.C. A&T Transportation Centers Host Successful Two-Day Symposium

04/22/2024 in College of Business and Economics , College of Engineering

N.C. A&T Board of Trustees to Hold Committee and Full Board Meetings April 25 and 26

04/19/2024 in Research and Economic Development